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1 Summary 
Phosphate regulating Hormone with homologies to Endopeptidases on the X- 
chromosome (PHEX, formerly identified as PEX) is the gene responsible for the 
hereditary disease X-linked hypophosphatemic rickets (XLH) and affects one in twenty 
thousand people, making it the most common form of rickets.  A homologous disease has 
also been identified in Mus musculus and given the label Hyp for Hypophosphatemia.  
The cause of both diseases is an inactivation of the carboxy terminal end of the gene 
through mutation or deletion.  It has been demonstrated that PHEX affects the pathway or 
regulatory elements for the expression of the renal sodium dependant phosphate 
transporter, NPT2a, and therefore phosphate resorption in the kidney. In a separate 
regulatory pathway PHEX affects the mineralization of osteoid, the scaffolding of hard 
bone. 
 
In this thesis, I have created and analyzed transgenic mouse strains overexpressing 
hPHEX.  The transgenic animals were classified by PCR and PHEX was pinpointed by in 
situ hybridization to be expressed in trabecular and cortical bone as expected.  
Phenotypical analysis of transgenic animals demonstrated that biochemical measurements 
were not affected by the presence of the transgene under the control of a ubiquitous 
promoter.  The transgenic hPHEX animals were crossed with Hyp mice to establish 
whether a rescue or partial rescue of the mutant phenotype was possible.  Phenotypical 
analysis of the rescue mice indicated an improvement in body weight and bone 
morphology, including mineralization, over the mutant hyp mice, while most biochemical 
parameters remained unchanged.   
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2 Introduction 
Skeletogenesis is one of the most profound events in embryonic development, though it is 
one of the last to occur.  Its continuing evolvement throughout the life of an organism 
makes bone, its precursors and associated factors a complex field of research.  The 
skeleton has three primary functions to fulfill.  First it is a mechanical device to give 
support and in connection with muscles facilitates voluntary movement.  Secondly, it 
provides a storage compartment for ions, namely calcium and phosphate.  Finally, it 
protects vital organs from external trauma.  
 
It is the ability of bone to store large amounts of phosphate that underlies the goal of this 
thesis.  Phosphate is a major constituent of bone mineral, which is laid down in the form 
of hydroxyapatite (3Ca3(PO4)2·Ca(OH)2) (Landis et al., 1995).  With numerous pathways 
leading to the regulation of phosphate in the body, it is a rare situation that a 
physiological change in phosphate can be attributed to a single gene product.  First 
identified in 1995 by the Hyp Consortium, a Phosphate regulating gene with homologies 
to Endopeptidases on the X – chromosome (PEX) (Hyp consortium, 1995) (now 
identified as PHEX) is one such gene.  A loss of function mutation in the carboxy-
terminal region of this gene leads to X-linked hypophosphatemic rickets (XLH).  A 
mouse model of this disease is found in the Hyp mouse, which carries a spontaneous 
deleterious mutation in the 3’ region of the mouse PHEX (mPHEX) gene (Eicher, 1976).  
These homologous diseases are mainly characterized by hypophosphatemia, but also 
include increased alkaline phosphatase (ALP), bone deformity, normal serum calcium, 
normal PTH and inappropriately normal levels of active vitamin D3. 
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The major site of expression of PHEX in human and mouse is in mature osteoblasts of 
calvaria and long bones, odontoblasts, with minor expression in lung, muscle, ovary and 
human parathyroid gland but specifically not in kidney (Beck et al., 1997; Du et al., 
1996; Blydt-Hansen, 1999).   
 
The aim of my doctoral work was to create and characterize two transgenic mouse lines.  
The first transgenic lineage was to overexpress the human PHEX (hPHEX) gene under 
the control of an osteocalcin gene promoter, in order to achieve osteoblast specific 
expression.  The second line would overexpress hPHEX under control of a β-actin 
promoter for ubiquitous expression.  These two lines were then analyzed for phenotypical 
changes.  Transgenic animals expressing hPHEX were further crossed with the Hyp mice 
in order to rescue the phosphate wasting and osteoblast mineralization defect that 
characterize these mutant animals. 
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2.1     Osteogenesis 
 
2.1.0  Physiology of bone 
 
Bone is comprised of varied cell types, minerals and extracellular matrix.  The cells of 
bone include chondrocytes, osteoblasts (OB), osteocytes and osteoclasts (OC).  
Osteoblasts and chondrocytes both differentiate from the mesenchymal cell lineage.  The 
osteoblast is similar to the fibroblast.  In fact, OBs express all gene markers of the 
fibroblast and only two known specific markers (Ducy et al., 2000). Osteocytes are 
mature OBs that have become entrapped within the matrix which they created.  
Osteoclasts are of hematopoietic origin and differentiate from the 
mononuclear/phagocytic lineage (Hattersley et al., 1991).   
 
There are two physiologically different types of bone (flat and long) derived from 
intramembranous or endochondral ossification, respectively.  The parts of the long bones 
are classified as either compact bone (cortical) or spongy 
bone (trabecular).  Bone is defined by the amount of 
matrix, created by OBs, that has been mineralized. 
Cortical bone is generally 80-90% mineralized, whereas 
trabecular bone remains mostly unmineralized, with only 
15-25% mineralization.  Trabecular bone houses the 
hematopoietic bone marrow as well as blood vessels and 
connective tissue (Baron et al., 1999).  (fig 1). 
Figure 1 
Long bone architecture 
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During embryonic development chondrocytes lay down the anlagen or templates for 
intermembranous bones that will later be calcified.  Within the growth plate of long 
bones, between the epiphysis and metaphysis, it is the chondrocytes that allow for 
endochondral growth.  Within the growth plate, chondrocytes are organized into columns 
of cells that differentiate through highly regulated temporal signaling.  From furthest to 
closest to the ossification center of the bone is the reserve or resting zone, proliferating 
chondrocytes, transition zone, upper hypertrophic chondrocytes, lower hypertrophic 
chondrocytes and osteoblasts.  Proliferation and differentiation of the chondrocytes is 
driven by indian hedgehog (Ihh) and parathyroid hormone-related peptide (PTHrP), 
which are expressed in the hypertrophic chondrocytes and proliferating chondrocytes, 
respectively (St-Jacques et al., 1999).  It is between the lower hypertrophic chondrocytes 
and the metaphysis that initial calcification of the cartilage occurs (Wallis, 1996).    After 
formation of the cartilage, capillaries invade allowing for migration of osteoblasts and 
subsequent bone formation, followed later by bone resorption activity of osteoclasts. 
 
 
2.1.1  Osteoblastogenesis 
 
The cellular maturation and differentiation from stem cell to osteoblast (OB) and 
osteocyte is not well understood at this time.  Several specific markers as well as 
stimulators and inhibitors of differentiation for each of the various stages, leading to OBs 
have been identified.    Alkaline phosphatase (ALP) and osteocalcin are generally 
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accepted OB markers.  The transcription factor Cbfa1 induces differentiation toward OB 
while Msx-2 has been shown to inhibit the progression (Takeda, et al., 2001).  Some of 
the other factors involved in OB differentiation include transforming growth factor β 
(TGF-β), Parathyroid hormone (PTH), Parathyroid hormone related protein (PTHrP), 
1,25 dihydroxyvitamin D3 (1,25(OH)2 D3) and bone morphogenetic proteins (BMPs) 
(Ducy et al., 2000).   
Once the pre-osteoblast is signaled to stop proliferating and to differentiate, it changes 
shape from a spindle like cell to a large cuboidal OB.  Mature OBs have large nuclei, an 
enlarged golgi complex and extensive ER.   Osteoblasts form in clusters of cells (~100 to 
400 cells per cluster) at each bone forming site.  They are able to secrete osteoid 
(unmineralized extracellular matrix) in a specific direction where mineralization is 
desired.  Within the osteoid, calcium and phosphate ions accumulate and once the osteoid 
components have matured, hydroxyapatite crystals bind to the type I collagen fibers 
through glycoproteins.  While the osteoid is mineralized and bone apposition occurs, 
some osteoblasts become trapped within the new growth and mature into osteocytes. 
Osteocytes express different cell markers than the osteoblast and lining cells, for 
example, SB3 and CD44 (Aubin et al., 1995; Hughes et al., 1994). 
 
 
2.1.2  Osteoclastogenesis 
 
As a living organ, bone is constantly being built and resorbed at varying rates throughout 
the life of an organism.  This process, called remodeling, is unique to bone.  Bone is the 
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only organ whose constitutive cells work to destroy the organ itself.  Compared to OBs, 
the function of osteoclasts (OCs) is much better understood. 
 
Osteoclasts are the last of the skeletal cells to appear during embryogenesis.  Their 
differentiation is under the control of numerous transcription factors and varied secreted 
molecules.  The earliest known regulator of OC differentiation is the transcription factor 
Pu.1, which controls both macrophage and OC lineage differentiation.  Other 
transcription factors involved include NF-κB, c-fos and mi.  Secreted factors responsible 
for function and activity as well as differentiation include macrophage colony stimulating 
factor (M-CSF), osteoprotegrin (OPG), OPG ligand (OPGL) (Kong et al, 1999), 1,25-
dihydroxyvitamin D (1,25(OH)2D3)  , RANK ligand, TNF receptor-associated factors 
(TRAFs) and C-SRC (Teitelbaum, 2000).  OPG inhibits osteoclast differentiation and 
overexpression leads to an increase in bone mineral density (Simonet et al., 1997).   All 
of the different factors which have regulatory influence are further involved in positive 
and negative feedback loops, as shown by the regulation of NF-κB by TRAFs, the 
regulation of M-CSF receptors by Pu.1 (Tondravi et al, 1997) or the stimulation of OPG 
secretion from osteoblastic lineages by (1,25(OH)2D3) (Hofbauer, 1998). 
 
Osteoclasts are giant multinucleated cells that are found in contact with calcified bone 
surfaces.  The side of the OC facing the bone surface forms a pocket enclosed by a 
sealing zone.  The membrane of the OC within this compartment is highly folded making 
a ruffled border area ideal for maximizing transport capabilities.  Enzymes and 
metalloproteinases are secreted into this pocket via vesicle transport.  The pH is lowered 
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within the compartment through the use of a proton pump and the lysozymal enzyme 
cathepsin K (Baron, 1989; Li, 1999).  The low pH within the compartment dissolves 
hydroxyapatite crystals allowing the degradation of the remaining collagen fibers.  
Phosphate and calcium released via this process is either released during breaks in the 
sealing zone, or by transport across the cell (Baron et al., 1989).   
The process of remodeling trabecular bone takes 3 to 4 months to complete.  The process 
starts with the activation of the remodeling activity and continues through the phases of 
resorption, reversal phase, formation and finally resting.  Activation can be in response to 
growth, repair or humoral factors. 
 
 
2.2     Phosphate regulation 
 
Phosphate is an ion that is important for many cellular functions and involved in 
structural stability of lipid membranes.  It is important for there to be a sufficient source 
of inorganic phosphate available from internal sources.  The average adult human 
contains 600g of phosphorous with concentrations of 1.8 – 2.2 mg/dL in serum.  The 
concentrations are not as tightly regulated as other ions such as calcium (Broadus, 1999).  
The concentration varies throughout the day and can vary due to age, sex, diet and 
hormone concentrations.  Fifteen percent of inorganic phosphate is protein bound while 
the rest circulates as complexed monohydrogen or dihydrogen phosphate.  Phosphate 
excretion and resorption in a normal adult human is regulated so there is no net loss or 
gain of phosphate.  Approximately eighty-five percent of inorganic phosphorous is 
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reabsorbed in the renal proximal tubules.  In various metabolic diseases the renal 
phosphate reabsorption is compromised and dietary intake can not make up for the loss.   
 
2.2.1  1,25 dihydroxyvitamin D3 (calcitriol) 
Biologically active 1,25-dihydroxyvitamin D (1,25(OH)2D3) and parathyroid hormone 
(PTH) are the two most influential hormones in ion homeostasis in bone.  Inert vitamin D 
is processed in the kidney and liver into its active form.  Upregulation of 1,25(OH)2D3 
increases the rate of intestinal absorption of phosphate and calcium ions.  Increased 
concentrations of 1,25(OH)2D3 are also associated with upregulation of OPG (inhibition 
of osteoclast formation) and down regulation of osteoblastic PHEX expression in vitro 
(Hofbauer et al., 1998; Ecarot and Desbarats, 1999).  Long term hypophosphatemia is 
one cause of upregulation of 1,25(OH)2D3.  In the hypophosphatemic vitamin D resistant 
rickets mouse model (Hyp) it was shown that 1,25(OH)2D3 action  on osteoblasts was 
dependent on extracellular Pi concentrations, as measured by alkaline phosphatase (ALP) 
activity in vitro (Yamamoto et al., 1992).  One of the phenotypical abnormalities of the 
Hyp mouse is the abnormally normal levels of 1,25(OH)2D3 in the presences of 
hypophosphatemia. 
 
2.2.2 Parathyroid Hormone / Parathyroid Hormone related Protein 
PTH is a highly conserved protein consisting of 84 amino acids in all known mammals 
and is exocytosed by the parathyroid gland.  PTH is able to stimulate the release of both 
calcium and phosphate ions from bone.  In kidney, PTH has opposite actions on the two 
ions.  Renal phosphate reabsorption is inhibited and calcium renal reabsorption is 
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stimulated.  PTH interacts with calcium, phosphate and 1,25(OH)2D3 as part of a complex 
regulatory mechanism to control serum calcium and phosphate ion levels.  Serum 
calcium levels have the most profound affect on PTH production, where hypercalcemia 
inhibits and hypocalcemia stimulates PTH production.   1,25(OH)2D3 actions are similar 
to those of calcium, while phosphate stimulates both secretion of PTH and parathyroid 
gland cell proliferation (Slatopolsky et al., 1996).   
Parathyroid hormone related protein (PTHrP) was the second member of the PTH family 
described as a tumor product and identified as the causative factor in humoral 
hypercalcemia in malignancy (HHM) (Wysolmerski, 1994).  PTHrP is a polyhormone 
with multiple splice variants, creating three isoforms of 139, 141, and 173 amino acids.  
PTH and the amino terminal PTHrP share a common receptor, the PTH/PTHrP receptor.  
The PTH/PTHrP receptor is found in varied tissues, but most abundantly in kidney and 
bone (Lee et al., 96).   PTH and PTHrP also have other separate and unique receptors, 
though some of their biological functions have yet to be elucidated.  PTHrP is expressed 
in multiple tissues, with varying actions.  Expression found in bone inhibits bone 
resorption and in chondrocytes it is demonstrated to promote proliferation while 
inhibiting terminal differentiation and apoptosis (Lee et al., 96).  PTHrP expressed in 
chondrocytes is controlled by the developmental patterning gene Indian Hedgehog, which 
is expressed by prehypertrophic chondrocytes (Vortkamp et al., 1996).  Increased levels 
of PTH (associated with hyperparathyroidism), through indirectly increased osteoclast 
activity, lead to the release of calcium and phosphate ions from bones.  In distal proximal 
tubules of the kidney phosphate is primarily reabsorbed through a sodium dependant 
cotransporter (Npt2).  Increased levels of PTH act to degrade Npt2, therefore leading to 
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fewer membrane bound sodium dependant phosphate transporters and renal phosphate 
wasting (Pfister et al., 1998).    
 
  
2.3  Phosphate regulating hormone with homologies to  
  Endopeptidases on the X – chromosome (PHEX) 
 
2.3.1  X-Linked Hypophosphatemic Rickets 
X-linked hypophosphatemic rickets (XLH) is an X-linked dominant disorder that has 
little or no gene dosage effects and affects close to 1:20000 people (Whyte et al., 1996).  
The XLH disorder is characterized by hypophosphatemia, a short stature (including lower 
extremity deformation), tooth abscesses, enthesopathy, increased alkaline phosphatase 
(ALP), normal serum calcium, normal PTH and inappropriately normal levels of 
1,25(OH)2D3.  Hypophosphatemia, which is the only consistent characteristic of this 
disorder, is caused by renal phosphate wasting in the proximal tubule.  This wasting has 
been attributed to the reduction in both RNA and protein levels of the high affinity, low-
capacity Na+ dependent phosphate transporter type II (NPT2) by 50% (Tenenhouse et al., 
1994).  Fluorescent in situ hybridization studies of NPT2 located its chromosomal 
position at 5q35, excluding it as a causative gene for XLH.   
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2.3.2 Hyp, mouse model for XLH 
 
In 1966, six mice were observed to have a shortened trunk and hind limbs.  These mice 
were bred further and eventually backcrossed into the C57BL6/6J background.  These 
mice, identified by the symbol Hyp, were described in 1976 as being the mouse 
homologue to XLH (Eicher et al., 1976.  Hyp mice present the same phenotypical 
evidence as XLH, most importantly:  hypophosphatemia, shortened hind limbs and 
inappropriately normal levels of 1,25(OH)2D3.  To examine osteoblast function, normal 
periosteum and osteoblasts from Hyp and normal mice were transplanted into the gluteal 
muscle of normal and Hyp mice.  As expected, the normal matrix implanted into Hyp 
mice did not mineralize normally.  The Hyp cells transplanted into normal mice did not 
show a complete mineralization as the normal cells transplanted into normal mice did.  
This inability to achieve normal mineralization indicates that Hyp mice also have a 
primary osteoblast defect (Ecarot-Charrier et al., 1988).   
In order to see if the causative factor was circulating or not, Hyp mice were used in a 
parabiosis experiment.    Hyp mice were joined to normal littermates allowing sharing of 
circulating factors. In both short and long term analysis of phosphate levels the normal 
littermate develops hypophosphatemia (Meyer et al., 1989).  Transplantation studies of 
the Hyp kidneys into normal mice and of normal kidneys into Hyp mice identified no 
primary renal defect, but rather an intrinsic defect of the environment within the Hyp 
mouse (Nesbitt et al., 1992). 
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2.3.3  Identification and characterization of PHEX 
The phosphate regulating gene with endopeptidase activity on the X chromosome 
(PHEX) was identified in 1995 through positional cloning by the efforts of the Hyp 
Consortium, in an effort to find the gene responsible for XLH.   The gene is comprised of 
22 small exons spread over 220Kb of genomic DNA.  It encodes a 749 amino acid 
protein which is a type II integral membrane glycoprotein of the family of neutral 
endopeptidases.  Other members of this family include neprilysin (NEP), endothelin 
converting enzyme 1 and 2 (ECE-1 and ECE-2) and the KELL antigen (KELL).   PHEX 
has a short N-terminal region, a single transmembrane domain and a long carboxy 
terminal region containing the catalytic site (Hyp Consortium, 1995).  Conserved features 
include ten cysteine residues, a pentapeptide zinc binding motif (HEXXH), a second zinc 
binding motif (ENXADXGG), and N-glycosylation sites (Oefner, 2000).  It has been 
proposed that PHEX is an inactivating endopeptidase.  At this time the definitive 
substrate(s) for PHEX have not been identified, though fibroblast growth factor 23 (FGF-
23) does seem a likely candidate (Bowe, 2001). 
 
In one study, 83% of XLH patients had missense or deletion mutations in the 3’ region of 
the PHEX gene (Rowe, 1997).  The Hyp mouse was also found to have a 3’ deletion in 
the PHEX gene between exons 15 and 16.   Expression of PHEX is localized to flat and 
long bone, teeth, lung, muscle, ovary and human parathyroid gland (Beck et al., 1997; Du 
et al., 1996; Blydt-Hansen et al., 1999).  Bone and teeth show a much higher level of 
expression than other tissues and there is no expression in the kidney.  This is interesting 
as many endopeptidases have been shown to have high expression at the point of activity.   
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2.3.4  Endopeptidase activity 
The first evidence of endopeptidase activity came from cleavage experiments on PTH.  
Recombinant hPHEX transiently expressed in COS-7 cells was incubated with both 
human PTH (1-38) and (1-34).  Cleavage products of PTH were seen by reverse phase 
high pressure liquid chromatography (HPLC) for both species and were not detected 
when incubated with vector transfected COS-7 cells (Lipman et al., 1998)  Further 
examination of PHEX endopeptidase activity used a secreted form of PHEX (secPHEX) 
that involved deletion or replacement of amino acids in the signal peptide / membrane 
anchor domain (SA domain).  The secreted form was purified from cultured LLC-PK 
cells and assayed for activity with multiple human substrates to include: PTH1-34, 
PTH1-84, [Leu]enkephalin, PTHrP1-34, PTHrP107-139, big-endothelin-1, endothelin-1 
and others.  The only substrate showing cleavage was PTHrP107-139 (Boileau et al., 
2001).  This study indicates that the extracellular catalytic domain of PHEX requires 
interaction with other membrane proteins for true physiological activity.  More recently it 
was shown that PHEX can cleave wild-type FGF-23, but not the mutant FGF-23 (FGF-
23(R179Q)) found to be the cause of autosomal dominant hereditary rickets (ADHR) 
(ADHR Consortium, 2000). A high level of FGF-23 expression has been found in tumors 
from patients with tumor-induced osteomalacia (TIO).  Expression of FGF-23 in 
osteoblasts has thus far proved to be negative, and the biological point of expression has 
been shown only in brain and thymus (Yamashita, 2000).  TIO is also known as 
oncogenic hypophosphatemic osteomalacia (OHO) and displays the same phenotypical 
characteristics as for XLH patients (Kumar, 2000).  The secreted FGF-23 protein from 
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tumors found in patients with this disorder is a circulating factor with a molecular mass 
of 32kDa (White et al., 2001).   
ZAAL-pNA and [Leu]enkephalin, the substrates for ECE1 and NEP respectively, have 
been demonstrated to be cleaved by PHEX.  The catalytic domain of NEP was 
crystallized and using sequence homology compared to other endopeptidases.  The C 
terminal domain retains 39% similarity which is enough to suggest common tertiary 
folding patterns.  Ten cysteine residues involved in disulfide bridges, 3 zinc binding 
residues and 6 ligand binding residues are also conserved between the two proteins 
(Oefner et al., 2000).   
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2.4     Goal of this project 
 
In this doctoral work we attempted to create transgenic mouse lineages expressing 
hPHEX through the use of pronuclear injection using two different transgene constructs.  
The first transgene contained the hPHEX cDNA under the control of the osteocalcin 
promoter (OG2) for specific expression of hPHEX in osteoblasts.  The second transgene 
used the β-actin promoter for ubiquitous expression of the hPHEX cDNA.  Once 
expression of hPHEX in the two lineages was established, the lineages were analyzed for 
phenotypical differences.  Analysis included, but was not limited to, body weight, serum 
and urine phosphate, calcium, and potassium levels, serum PTH, ALP and creatinine, 
bone length and densitometry, immunohistochemical staining and in situ hybridization.  
Mice showing expression of hPHEX were then bred with Hyp mice.  The offspring were 
subjected to the same phenotypical analysis to determine if a rescue of the Hyp 
phenotype was possible from osteoblast specific or ubiquitous overexpression of hPHEX. 
Due to negative expression in the first OG2 transgenic mice, only the transgenic mice 
with ubiquitous expression of hPHEX and subsequent rescue mice were analyzed during 
this doctoral work.   
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3    Materials and methods 
3.1 Materials 
 
3.1.1   Solutions and buffers 
 
1x TBE 
100 mM Tris-HCl, pH 8.3 
43 mM Boric acid 
2 mM EDTA 
autoclave 
5x DNA-Loading buffer 
40 % (w/v) Sucrose 
0.25 % (w/v) Xylene cyanol 
0.25 % (w/v) Bromphenol blue 
  in 5x TBE 
Protein staining  
Brilliant Blue R250-concentrate diluted in 
H2O(Sigma) 
Destain Solution 
40 % (v/v) Methanol 
10 % (v/v) Acetic acid, 
in H2O 
Cellophane prep solution 
25%  Ethanol 
5% Glycerol 
5x SDS-Loading buffer 
65 mM Tris-HCl, pH 6.8 
10% (v/v) Glycerol 
2.3% (w/v) SDS 
0.01% (w/v) Bromphenol blue 
(5% (v/v) β-Mercaptoethanol 
10x SDS-PAGE-Running buffer 
250 mM Tris base 
1.9 M Glycine 
1% (w/v) SDS 
1X TNE 
10 mM  Tris-HCl pH 7. 
500 mM  NaCl 
1 mM  EDTA 
1x TNT 
10 mM Tris-HCl, pH 8.0 
150 mM NaCl 
0.05% (v/v) Tween 20 
Ponceau staining  
0.1% (w/v) Ponceau S (Sigma) 
5% (w/v) Acetic acid 
in H2O 
2x BBS 
50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
sterile filtered 
20x SSC pH 7.0 
3 M  NaCl 
0.3 M Sodium citrate dihydrate 
1x PBS 
137 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
autoclaved 
TBST 
0.04% (v/v) Tween 20, in TBS 
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10x BTPE 
100 mM  PIPES 
300 mM Bis-Tris 
autoclaved 
1X solution is pH 6.5 
 
PET 
500 ml PBS (1x) 
0.005% (w/v) EDTA (Sigma) 
0.05% (w/v) Trypsin, 
(PBS autoclaved, EDTA and 
Trypsin sterile filtered) 
Gelatin solution 
10 g powdered gelatin 
0.05% Thymol-Kristall antimicrobial 
bi-distilled water to 1000ml 
stored at 4°C for 2 weeks 
Glyoxal mix 
10% (v/v) 6M Glyoxal, deionized 
(Sigma) 
10% (v/v) 10x BTPE 
75% (v/v) DMSO 
5% (v/v) 80% Glycerol (sterile) 
stored at -80°C, thawed only once 
 
Chromealium -Gelatine solution 
1000 ml Gelatin solution 
40 ml Chromealium solution 
stored at 4°C for 1 week 
 
Chromealium Solution 
4 g  Chromealium (Kalium- 
 Chrom(III)-Sulfat) 
bi-distilled water to 100ml 
 
stored in dark at room temperature  
MMA I 
60 ml  Methylmethacrylate 
35 ml  Butylmethacrylate 
5 ml   Methylbenzoate 
1.2 ml  Polyethyleneglycol 400 
 
APES solution 
4 ml  APES (Sigma) 
200 ml  Acetone 
MMA III 
60 ml  Methylmethacrylate 
35 ml Butylmethacrylate 
5 ml   Methylbenzoate 
1.2 ml  Polyethyleneglycol 400 
0.8 g   Benzoylperoxoid 
MMA II 
60 ml  Methylmethacrylate 
35 ml  Butylmethacrylate 
5 ml   Methylbenzoate 
1.2 ml  Polyethyleneglycol 400 
0.4 g   Benzoylperoxoid 
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In situ Hybridization solution 
50%  Formamide 
10 mM  Tris-HCl pH 7.6 
200 µg/ml  tRNA 
1X  Denhardts solution 
10%  Dextran Sulfate 
600 mM  NaCl 
0.25 %  SDS 
 to 100 % volume 
MMA polymerization mixture I 
60 ml  Methylmethacrylate 
35 ml  Butylmethacrylate 
5 ml   Methylbenzoate 
1.2 ml  Polyethyleneglycol 400 
0.8 g Benzoylperoxoid 
400 µl  N,N-Dimethyl-p-toluidin 
 Denhardts Solution (100X) 
5 g  Ficoll 400 
5 g  Polyvinylpyrolidone 
5 g  BSA 
Bi-distilled water to 250 ml then filtered at 
0.45 µm then stored in 50 ml aliquots at       
-20°C 
 
 
Ready to use solutions, buffers and materials 
 
Roti-Phenol     Carl Roth GmbH 
Roti-Phenol/Chloroform  Carl Roth GmbH 
NTB-2 Nuclear Track Emulsion Integra Biosciences;  
Trizol     Invitrogen 
Nitroplus supported Nitrocellulose Sud-Laborbedarf  
 
 
3.1.2  Cell lines and Bacterial strains 
 
 
Mammalian Cell lines 
 
293-EBNA Human Embryonic Kidney including nuclear 
Epstein-Barr antigen 
     Invitrogen, Karlsruhe, Germany 
Catalog no. R620-07  
   
COS-7       African Green Monkey Kidney   
 DSMZ - Deutsche Sammlung von Mikro- 
  organismen und Zellkulturen GmbH 
  Braunschweig, Germany 
 
E. Coli 
 
DH5α T1R: F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 
deoR 
 recA1 endA1 hsdR17(rk- , mk+) phoA supE44 
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thi-1gyrA96 relA1 tonA  
                        
TOP10:  F- mcrA ∆(mrr-hsdRMS-mcrBC) 
                        φ80lacZDM15 ∆lacX74 deoR recA1 araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG  
                         
BL21 (DE3) pLysS: F- ompT hsdSB (rB-mB-) gal dcm 
                        (DE3) pLysS (CamR) 
3.1.3  Bacterial and Eukaryotic cell culture 
 
All media are autoclaved after preparation or the components are sterile filtered. 
 
 
LB-Medium 
1% (w/v)  Tryptone peptone (Difco) 
0.5% (w/v)  Yeast extract (Difco) 
0.5% (w/v)  NaCl 
0.01% (v/v)  10 M NaOH, 
autoclaved 
 
Plates are made with the additon of 1.0 % 
(w/v) Agar (Difco) before autoclaving.  
Antiboditics are added and plates are 
poured at 50°C 
SOC-Transfection media  
2 % (w/v)  Tryptone peptone (Difco) 
0.5 % (w/v)  Yeast extract (Difco) 
10 mM  NaCl 
10 mM  MgCl2 
10 mM  MgSO4 
2.5 mM  KCl 
autoclaved 
20 mM.   Glucose (sterile filtered) 
RPMI 1640 media (pH 7,0-7,2) 
500 ml  RPMI 1640 C 
10%(v/v)  FBS (Invitrogen) 
2 mM  L-Glutamin 
  (Glutamax™II, Invitrogen) 
100 µg/ml  Streptomycin  
100 U/ml  Penicillin (Invitrogen) 
0.5 µg/ml  Fungizone (Invitrogen) 
Selective Antibiotics 
Bacterial 
50 µg/ml  Ampicillin(Sigma) 
Eukaryotic 
350 µg/ml  G418(Invitrogen) 
or 
500 µg/ml  Zeocine(Invitrogen) 
dependent on cell line 
DMEM/F12 media (pH 7,0-7,2) 
500 ml  DMEM/F12 (Invitrogen) 
10%(v/v)  FBS (Invitrogen) 
2 mM  L-Glutamin 
  (Glutamax™II, Invitrogen) 
100 µg/ml  Streptomycin (Invitrogen) 
100 U/ml  Penicillin (Invitrogen) 
350 µg/ml  G418 (for selection of 
transfected   cells only) 
0.5 µg/ml  Fungizone (Invitrogen) 
Serumfree (conditioned) Media 
500 ml  DMEM/F12 (Invitrogen) 
2 mM  L-Glutamin 
  (Glutamax™II, Invitrogen) 
100 µg/ml  Streptomycin (Invitrogen)  
100 U/ml  Penicillin (Invitrogen) 
0.5 µg/ml  Fungizone (Invitrogen) 
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Transfection Media 
90% (v/v)  DMEM/Eagle (Serva) 
10% (v/v)  FBS (Invitrogen) 
2 mM  L-Glutamin 
  (Glutamax™I, Invitrogen) 
100 µg/ml  Streptomycin (Invitrogen) 
100 U/ml  Penicillin (Invitrogen) 
0.5 µg/ml  Fungizone (Invitrogen) 
Freezing Media 
50% (v/v)  DMEM/F12 or RPMI 1640 
40% (v/v)  FBS (Invitrogen) 
10% (v/v)  DMSO 
 
 
 
3.1.4 Enzymes 
 
Restriction endonucleases New England Biolabs; Frankfurt a. Main, 
Germany 
 Roche Diagnostics; Mannheim, Germany 
 
T4 DNA ligase New England Biolabs; Frankfurt a. Main, 
Germany 
 
AmpliTaq DNA polymerase Roche Diagnostics; Mannheim, Germany 
 
Superscript II Reverse  Roche Diagnostics; Mannheim, Germany 
Transcriptase 
 
Alkaline Phosphatase Roche Diagnostics; Mannheim, Germany 
 
Sequenase 7-deaza dGTP USB; Cleveland, Ohio, U.S.A 
DNA Sequencing kit 
 
RNase A Sigma; Diesenhofen, Germany  
 
DNA Polymerase I New England Biolabs; Frankfurt a. Main, 
Germany 
Large (Klenow) Fragment 
 
Proteinase K Sigma; Diesenhofen, Germany 
 
T3 RNA Polymerase Promega; Mannheim, Germany 
SP6 RNA Polymerase 
T7 RNA Polymerase 
 
T4 polynucleotide kinase New England Biolabs; Frankfurt a. Main, 
Germany 
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3.1.5  Oligonucleotides 
 
All oligonucleotides were synthesized by Metabion GmbH. (www.metabion.com) 
Martinsried, Germany 
2.1.6   Primers 
 
All oligonucleotides were produced by Metabion, Martinsried.   
 
pCDNA AS Intron 5’ – TTC CAC CAC TGC TCC CAT TCA TC – 3’ 
PHEX2 5’ – GTT ATG CTC ATG TGA GGT GC – 3’ 
Hyp ex3sense 5’ – TCT TGT CAA ACA GTG TTC TGG – 3’ 
Hyp ex3antisense 5’ – CCA GGG AGA CAT TTG AGG AG – 3’ 
Hyp 19sense 5’ – GCT TGG GCT AGT TTG CTA TCT C – 3’ 
Hyp 19antisense 5’ – TGA GTT GGT GCT ATA CAC GGA G – 3’ 
RHP4 5’ – GCT GGC ACT GTG CAA CTG TCT – 3’ 
OC Sense 5’ – TCT CTC TGC TCA CTC TGC TG– 3’ 
OC antisense 5’ – AGA GCA GCC AAA GCC GAG C– 3’ 
 
 
3.1.7  Vectors 
 
pCDNA4/HisMax  Invitrogen; Karlsruhe, Germany 
 
pCDNA Invitrogen; Karlsruhe, Germany 
 
pBluescript Stratagene; Heidelberg, Germany 
 
pBI Clontech; Palo Alto, CA U.S.A. 
 
 
3.1.8  Isotopes 
 
α-32P-dCTP Amersham Pharmacia Biotech; 
 Freiberg, Germany  
 
α-32P-dATP Amersham Pharmacia Biotech; 
 Freiberg, Germany 
 
γ-32P-dATP Amersham Pharmacia Biotech; 
 Freiberg, Germany 
 
 
 
3.1.9  Antibodies 
 
Antibodies were purchased from Santa Cruz Biotechnology, CA, U.S.A.   
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3.1.10  Molecular weight and protein standards 
 
All DNA and RNA markers were obtained from New England Biolabs, Frankfurt a. 
Main, Germany (figure 2). 
 
 
 
3.1.11 Kits 
 
Geneclean II    Dianova; Hamburg, Germany 
 
DNA Maxiprep   Qiagen; Hilden, Germany 
 
Rat Intact PTH ELISA   Immutopics Inc; San Clemente, CA U.S.A. 
Osteocalcin    Immundiagnostik; Bensheim, Germany 
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3.2     Methods  
 
3.2.1  Sub cloning 
 
3.2.1.1  DNA plasmid cultures 
 
Bacteria containing the plasmid DNA of interest were suspended in 0.5 ml of LB and 
spread on a LB agar plate containing antibiotics specific to the plasmid being 
prepared.  In this work, all plasmids were selected for with ampicillin.  Using a flame 
sterilized glass rod, 250 µl and 100 µl of solution were spread on LB-agar plates (100 
µl ampicillin/ml) and incubated overnight at 37°C (minimum of 16 hours) to produce 
single isolated colonies.  
 
 
3.2.1.2  DNA Miniprep 
 
Two milliliters of LB media with 100 µl ampicillin/ml was inoculated with a single 
bacterial clone from a LB-agar plate and grown overnight at 37°C with constant 
agitation.  1.5 ml of the culture was centrifuged at 14,000 rpm for one minute in an 
eppindorf tube at room temperature.  The supernatant was removed and the pellet 
resuspended in 100 ml of ice cold solution I (50 mM glucose, 25 mM Tris-HCl pH 
8.0, 10 mM EDTA pH 8.0).  200 µl of solution II (0.2 N NaOH, 1% SDS) was added 
and mixed by inversion 5 – 10 times then incubated on ice five minutes.  150 µl of ice 
cold solution III (5 M KAc pH 4.8) was added, mixed, then incubated on ice for five 
minutes.  The solution was centrifuged five minutes at 14000 rpm and the supernatant 
transferred to a fresh tube.  An equal volume of phenol/chloroform (Roth) was added 
and vortexed, then centrifuged for five minutes at 14000 rpm at room temperature.  
The aqueous upper layer was transferred to a clean tube and mixed with an equal 
volume of phenol/chloroform/isoamyl alcohol (Roth) by shaking.  The solution was 
centrifuged for five minutes at 14000 rpm at room temperature and the aqueous layer 
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transferred to a clean tube.  DNA was then precipitated with one tenth w/v of NaAc 
pH 5.6 and two volumes of cold EtOH.  DNA pellet was then washed with 1 ml of 
70% EtOH, then air dried for ten minutes and resuspended in 30 µl TE pH 8.0.  One 
microliter of RNase A was added and incubated for 15 minutes at 37°C. 
 
  
3.2.1.3   DNA Maxiprep 
 
DNA maxipreps were prepared using Qiagen Maxiprep kits.  The protocol is briefly 
described here. 
 
150 ml of LB media was inoculated with antibiotics.  Cultures were then inoculated 
from a single clone and incubated overnight at 37°C (minimum of 16 hours) with 
constant agitation.  100 ml of culture was then centrifuged for ten minutes at 4000 
rpm.  Supernatant was discarded and the bacterial pellet resuspended in 10 ml of 
Buffer P1 (with RNase A added).  Ten milliliters of Buffer P2 were added and mixed 
by inversion five to ten times.  The solution was then transferred to a 40 milliliter 
centrifuge tube and ten milliliters of chilled Buffer P3 added.  The solution was 
incubated 20 minutes on ice then centrifuged 30 minutes in a GSA rotor at 4˚C at 
14000 rpm.  The supernatant was collected in a fresh centrifuge tube and centrifuged a 
second time for 20 minutes at 4°C at 14000 rpm to produce a cleared lysate.  Ten 
milliliters of buffer QBT were applied to a supplied Qiagen-tip 500 column and 
allowed to flow through by gravity.  The cleared lysate was then applied to the wet 
column and allowed to flow through by gravity.  The column was then washed twice 
with 30 ml of buffer QC.  The DNA was eluted from the column with 15 ml of buffer 
QF.  The DNA was then precipitated from the elutate in 30 milliliter glass corex tubes 
with 10.5 milliliters of isopropanol by centrifugation for 30 minutes at 14000 rpm and 
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4°C.  Pelleted DNA was washed with 5 ml of 70% EtOH and centrifuged 10 minutes 
at 14000 rpm and 4°C.  Precipitated DNA was air dried ten minutes and resuspended 
in 300 µl of TE pH 8.0.  OD260 and OD280 were read to determine concentration and 
quality. 
 
3.2.1.4  Restriction endonuclease digest 
   
3.2.1.4.1 Single digest 
 
Two microliters of DNA (1 ug/µl) were mixed with 3 µl of buffer, 3 µl 10X BSA (if 
required by enzyme), 2 µl of  restriction endonuclease 5 U/µl –20 U/µl), and 
bidistilled water to final volume of 30 µl.  Digestions were incubated two hours at the 
temperature recommended by the manufacturer. 
 
3.2.1.4.2 Double digest 
 
Two microliters of DNA (1 ug/µl) were mixed with 4 µl of buffer (compatible with 
both enzymes), 4 µl 10X BSA (if required by one of the enzymes), 2 µl of each 
restriction endonuclease and bidistilled water to final volume of 40 µl.  Digestions 
were incubated two hours at the temperature recommended by the manufacturer. 
 
3.2.1.4.3 Southern DNA digest 
 
Ten microliters of genomic DNA (tail lysis prep see Sec 3.2.1.0) were mixed with 4 
µl of buffer, 4 µl 10X BSA(if required by enzyme), 3 µl of  restriction endonuclease 
20 U/µl –100 U/µl), and bi-distilled water to final volume of  40 µl. The digestion was 
then mixed by passing through a pipet tip five times. Digestions were incubated four 
hours at the temperature recommended by the manufacturer. 
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3.2.1.5  DNA fragment purification 
 
Purifications were done using the Geneclean II Kit (Dianova).  An agarose gel was 
made dependant on the DNA size.  Fragments sized one kilobase or smaller were 
purified on a 1.2% agarose gel.  Those fragments larger than one kilobase were 
purified on 0.8% agarose gels.  Agarose was mixed with 100 milliliters TAE and 
boiled.  When cooled to 50˚C, 2 µl ethidium bromide (10 mg/ml, Roth) or vista green 
nucleic acid stain (Sigma, RPN5786) were added to the solution then poured into a gel 
chamber with comb and allowed to solidify.  The DNA samples were loaded in slots 
next to an appropriate sized DNA ladder and run at 5 V/cm of gel until separation of 
bands was achieved as determined by UV transillumination.  Using a sterile scalpel 
blade, the band of interest was cut from the gel and placed in a pre-tared eppindorf 
tube and weighed.  Three volumes of Ultrasalt (NaI) were added and the gel slice 
incubated at 50˚C for five minutes.  Glass silica was added 1 µl per µg DNA expected 
plus 1 µl (5 µg DNA would require 6 µl silica) and incubated for five minutes at room 
temperature.  DNA bound to the silica particles was centrifuged at 14000 rpm for 5 
sec and the supernatant discarded.  The pellet was washed twice with 1 ml of Ultra 
Wash and allowed to air dry for 10 minutes.  The DNA was eluted by stirring the 
pellet with 10 µl of TE pH 8.0, centrifuging at 14000 rpm for 5 seconds and removing 
the supernatant.  The supernatant was centrifuged a second time to remove all silica 
and the clean DNA supernatant placed in a fresh tube.  Purified DNA was quantified 
by UV260/280 spectrophotometery then stored at -20°C. 
 
 
 
3.2.1.6  Quantification 
 
Quantification of DNA and RNA was determined using cuvettes with 1cm path length 
in a Beckman DU 530 UV/VIS Spectrophotometer.  Two microliters of sample were 
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diluted in 198 µl of bi-distilled water and UV260 and UV 280 measured against a 
blank of bi-distilled water. 
 
µg DNA = (Absorbance)*(50)*(dilution factor)*(mL solution) 
 
 µg RNA = (Absorbance)*(40)*(dilution factor)*(mL solution) 
 
 
 
3.2.1.7  Phosphatase treatment 
 
Two microliters of DNA (1 µg/µl) were mixed with 1 µl dephosphorylation buffer, 1 
µl alkaline phosphatase and 6 µl bidistilled water then incubated for 60 minutes at 
37°C.  The enzyme was then inactivated by addition of 1/10th volume of 200 mM 
EGTA and heating at 65°C for 10 minutes. 
 
3.2.1.8  Ligation 
 
Ligation reactions were set up with molar ratios of 1 to 3 and/or 1 to 5 vector to insert.  
The formula for the amount of insert used is calculated as follows: 
 
ng of insert = [(ng of vector)(kb size of vector)(molar ratio of insert to vector)] / 
kb size of vector 
 
 
Generally 50 nanograms of vector were used per ligation reaction.  One microliter of 
T4 Ligase buffer was mixed with 1 µl of T4 ligase, 50ng vector DNA, corresponding 
molar ratio of insert DNA and bidistilled water to a final volume of 10 µl.  The 
reaction mixture was incubated overnight at 16°C.  Any ligation reaction not used for 
immediate transformation was frozen at -20°C. 
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3.2.1.9  Transformation 
 
Transformations were performed using heat shock (Stratagene).  DH5α cells, stored at 
-80°C, were thawed on ice for 30 minutes.  Five microliters of ligation reaction were 
added to the cells and incubated on ice for an additional 10 minutes.  Cells were 
incubated at 42°C for 2 minutes.  One milliliter of LB media was added to the cells 
and incubated for 1 hour at 37°C.  Cells were then pelleted by centrifugation at 5000 
rpm, the supernatant removed and the bacterial pellet resuspended in 200 µl fresh LB 
media.  100 µl and 50 µl of cells were spread with flame sterilized glass rods on LB 
plates containing 100 µg/milliliters ampicillin and grown overnight at 37°C.   
 
3.2.2   Cell culture 
 
Cos-7 (African green monkey kidney) cells were grown to confluence in DMEM with 
10% FBS (heat inactivated 56°C, 30 minutes), 10 U/ml penicillin streptomycin, and 
125 µg/ml Fungizone (Invitrogen) at 5% CO2 and 100% humidity. 
 
EBNA 293 human embryonic kidney cells were grown to confluence in DMEM with 
10% FBS (heat inactivated 56°C, 30 minutes), 10 U/ml penicillin streptomycin and 
125 µg/ml Fungizone (Invitrogen) at 5% CO2 and 100% humidity. 
 
 
 
3.2.2.1  Passaging 
 
Cells were passaged once they had achieved 90 – 100% confluence.  Media was 
removed by aspiration and cells washed with 10 milliliters of sterile PBS.  0.5 
milliliter of 0.05% Typsin/0.53 mM EDTA in PBS was added and the cells were 
incubated 5 minutes at 37°C until cells dissociated from the culture dish surface.  
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Cells were diluted and stained with 0.5% trypan-blue in PBS and counted with a 
hemacytometer using the following formula: 
 
cells/ml = (average number of cells per square)( dilution factor)(104) 
 
where each square is 1 X 1 mm and the depth is 0.1 mm.  5 X 104 cells/milliliter were 
then transferred to a fresh culture dish and pre-warmed media added to 10 milliliters. 
 
 
3.2.2.2  Freezing 
 
Media was removed from 75% confluent cells by aspiration and washed with 10 
milliliters of sterile PBS. 0.5 milliliter of 1X trypsin/EDTA (0.05% trypsin, 0.53 mM 
EDTA) in PBS was added and the cells were incubated 5 minutes at 37°C until cells 
dissociated from the culture dish surface.  Cells were then collected in 5ml media and 
centrifuged 5 minutes at 300X g in a swing bucket rotor.  Media was removed and 
cells were resuspended in 1 milliliter of freezing medium (60% media, 10% DMSO, 
30% FBS).  Cells were counted on a hemacytometer as previously described (3.2.2.1), 
and the cells further diluted to a concentration of 107 cells/milliliter and frozen in 1 
milliliter aliquots.  Cells were then frozen at -80°C overnight and then placed in liquid 
nitrogen for long term storage. 
 
3.2.2.3  Thawing 
 
Frozen cells were removed from liquid nitrogen and placed directly in a 37°C water 
bath until thawed (~ 1 minute). Five milliliters of media were added to the cell 
suspension then centrifuged 5 minutes at 300X g and the supernatant removed by 
aspiration.  The cell pellet was resuspended in 10 milliliters of media and placed in a 
10 cm culture dish to grow to confluency. 
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3.2.2.4  Transfection  
 
Transfections were performed using the Qiagen Effectene transfection kit.   
Transfections were performed according to the manufacture’s protocol for 100 mm 
culture dishes.  Cells for transfection were split the day prior to transfection at a ratio 
of 1 to 8.  Sixteen microliters of enhancer were added to 2 µg of DNA diluted in TE 
and the volume brought to 300 µl with bi-distilled water then mixed by vortexing.  
Samples were incubated for 5 minutes at room temperature then centrifuged briefly.  
Sixty microliters of effectene reagent was mixed in by vortexing 10 seconds and 
samples were incubated 10 minutes at room temperature.  One milliliter of growth 
medium was added and the transfection mix immediately added drop-wise to the 
newly passaged cells.  Growth medium was removed the next day, the cells washed 
once with PBS and fresh medium added.  Expression assays were then carried out 
after the appropriate incubation period. 
 
2.2.3   In vitro transcription and translation 
 
 
The TNT® Quick Coupled Transcription/Translation (Promega) system was used to 
determine if the constructs were capable of producing RNA and protein.  The 
manufacturer’s protocols were followed and are briefly described here. 
 
3.2.3.1 Transcription and translation reactions 
 
Two microliters of [35S]methionine (1000 Ci/mmol at 10m Ci/ml) were added to 40 µl 
TNT® Quick Master Mix and 7 µl bi-distilled water followed by one microliter of 
circular plasmid DNA (1 µg/µl).  The reaction mixture was mixed with a pipet tip and 
incubated for 90 minutes at 30°C.   
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3.2.3.2 Western gel analysis 
One to five microliters of sample were removed from the reaction mixture and added 
to SDS loading buffer.  The sample was loaded on a 4-12% bis-acrylamide pre-cast 
gel (Novex) and run for one hour in 1X running buffer at 200V.  The proteins in the 
gel were then stained with Brilliant Blue R250 for 10 minutes and the background 
stain removed with consecutive washes in destain solution.  The gel was then soaked 
in cellophane prep solution for 24 hours.  The moist gel was placed between sheets of 
cellophane and air bubbles removed by rolling with a glass rod.  The sandwiched gel 
was placed in a drying frame, the cellophane stretched tight, while excluding air 
bubbles, and left to dry. 
 
 
2.2.4   Animals 
 
C57BL/6J mice were obtained from The Jackson Laboratory, Bar Harbor Maine, 
U.S.A.  Hyp mice were a kind gift of Dr. Jueppner.  All animal were raised in 
accordance with German standard animal laboratory practices.  Rat/mouse breeding 
chow (Altromin #1314, Lage Germany) and water were available ad libitum to all 
animals except during overnight urine collection where food was restricted.   
 
 
3.2.5  PCR 
 
3.2.5.1  Amplification 
 
Polymerase chain reactions were carried out using a Perkin Elmer (PE) Applied 
Biosystems GeneAmp PCR System 9700 Thermocycler machine for all reactions 
except sequencing.  Sequencing reactions were carried out in a TRIO-Thermoblock 
(BIOmetra, Göttingen).  The annealing temperature was dependent on primer pairs 
and salt concentrations and determined using a PE Applied Biosystems GeneAmp 
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PCR System 9700 Thermocycler Tm utility program. 
 
3.2.5.2  Genotyping of PHEX transgenic animals 
 
The human PHEX transgene overexpressed in the mice was constructed to contain a 
SV40 poly A sequence from the vector pCDNA 1 (Invitrogen).  This sequence is of 
artificial origins is not found in known genomic DNA sequences and therefore 
specific to the transgene created.  PCR using one primer from this region and one 
primer from within the coding sequence of PHEX was used for the genotyping of 
transgenic animals. 
 
100 ng of genomic tail DNA was combined with 5 µl 10XPCR buffer, 3 µl 25 mM 
MgCl2, 2 µl 2.5 mM dNTPs, 1 µl 10 µM PHEX2 primer, 1 µl 10 µM pCDNA AS 
Intron primer, 0.5 U Taq polymerase and bi-distilled water to 50 µl.  PCR was carried 
out as follows: 
5 minutes 94°C 
30 cycles of   
45 seconds 94°C,  
45 seconds 64°C, 
45 seconds 72°C 
and 
7 minutes 72°C 
 
 
 
3.2.5.3  Genotyping of Hyp mice 
 
Hyp mice carry a spontaneous mutation that causes a deletion (between exons 15 and 
16) of the 3’ portion of the PHEX gene and can therefore be identified by multiplex 
PCR using primer sets from exon 3 and exon 19.    
 
100 ng of genomic tail DNA was combined with 5 µl 10XPCR buffer, 3 µl 25 mM 
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MgCl2, 2 µl 2.5 mM dNTPs, 1 µl 10 µM hyp ex3sense primer, 1 µl 10 µM hyp 
ex3antisense primer, 1 µl 10 µM hyp ex19sense primer, 1 µl 10 µM hyp 
ex19antisense primer, 0.5 U Taq polymerase and bi-distilled water to 50 µl.  PCR was 
carried out as follows: 
5 minutes 94°C 
30 cycles of   
45 seconds 94°C,  
45 seconds 58°C, 
45 seconds 72°C 
and 
7 minutes 72°C 
 
 
 
3.2.5.4  Sequencing 
 
Sequencing was performed using ABI Prism BigDye Terminator Cycle Sequencing.  
500 ng of DNA was mixed with 4 µl Big Dye, 5 pmol primer and filled to 10 µl with 
bidistilled water.  Reaction was overlaid with mineral oil and PCR carried out as 
follows: 
1 minute 96°C 
30 cycles of   
30 seconds 96°C,  
15 seconds 50°C, 
finished with 
4 minutes  60°C 
 
Analysis was performed by M. Boicu (Department of Molecular Structural Biology, 
MPI for Biochemistry, Martinsried) using a 373A DNA Sequencer (Applied 
Biosystems).  Computational analysis of DNA sequences were performed using DNA 
strider (Dr. Christian Marek) and pDRAW32 (AcaClone Software). 
 
3.2.5.5  Reverse transcription PCR (RT-PCR) 
One microliter of total RNA was mixed with one microliter oligo dT and 9 µl bi-
distilled water then incubated 10minutes at 70°C followed by a quick chill on ice.  
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One microliter dNTPs (10 mM), 2 µl DTT (100 mM) and 4 µl 5X first strand 
synthesis buffer were added to the RNA solution, mixed and incubated 2 minutes at 
42°C.  One microliter Superscript II was added and incubated 60 minutes at 42°C 
followed by 15 minutes inactivation at 70°C.  Four microliters of the RT reaction 
mixture was removed and used for PCR as described in section 3.2.5.2. 
 
 
3.2.6  Southern Blotting and hybridization 
 
3.2.6.1  Genomic DNA tail preparation 
 
One centimeter of mouse tail was placed in an eppendorf tube containing 500 ul tail 
lysis buffer, 100 µg/milliliter proteinase K (Sigma) and incubated overnight at 55°C 
with constant shaking.  Solution was shaken strongly by hand for 3 minutes then 
centrifuged for 10 minutes at 14000rpm to precipitate hair.  Supernatant was poured 
into a clean eppendorf tube with 0.5 ml isopropanol and inverted several times to 
precipitate DNA.  DNA was removed with a clean pipette tip and placed into 500 µl 
of bi-distilled water.  DNA was shaken by hand for 5 minutes or until DNA went into 
solution.  500 µl of phenol/chloroform/isoamylalcohol was added and mixed by 
inverting.  Mixture was centrifuged 5 minutes at 14000rpm at room temperature and 
the aqueous (upper) phase transferred to a clean eppi.  A second 
phenol/chloroform/isoamylalcohol extraction was performed with the aqueous phase 
again being transferred to a clean eppendorf.  The DNA was precipitated from the 
aqueous phase with 1/10 volume sodium acetate (pH 5.2) and 2 volumes ice cold 
ethanol, then centrifuged for 10 minutes at 4°C and 14000rpm.  Supernatant was 
removed and the pellet washed by inversion in 1 milliliter of 70% ethanol.  Pellets 
were then centrifuged 5 minutes at 4°C and 14000rpm, the supernatant removed and  
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the pellet air dried for 5 minutes at 50°C.  The DNA was resuspended in 40 µl of TE 
pH8.0 and stored at 4°C. 
 
3.2.6.2  Agarose gel electrophoresis 
 
A 0.8% agarose gel was prepared by dissolving 3.2g of agarose in 400ml of boiling 
1X TAE.  After cooling to 50°C with stirring, 12 µl of EtBr (10 mg/ml) was added 
and the agarose poured into a gel chamber, the appropriate gel comb set, then allowed 
to solidify.  1X TAE was added to the running chamber and the gel comb removed.  
10 µl of restriction enzyme digested genomic DNA was mixed with 2 µl of 6X DNA 
loading buffer and loaded into the wells with 500 ng of 1kb DNA ladder (NEB) 
loaded as a standard.  Agarose gels were run at room temperature and 2.5 V/cm of gel 
for a minimum of 8 hours.  DNA was visualized on a UV transilluminator next to a 
metric ruler and a digitized image kept for records. 
 
 
3.2.6.3  Transfer to solid support 
 
Agarose gel was soaked for 1 hour in denaturing buffer(0.6 M NaCl, 2 M NaOH),  
washed briefly with bidistilled water then soaked in neutralizing buffer (0.6 M NaCl, 
1 M Tris-HCl pH8.0) for 1 hour.  A gel sandwich was then created by overlapping 2 
sheets filter paper (Whatman 3mm) into 20X SSC buffer.  Gel sized layers were then 
placed on top of the first overlapping pieces of filter paper in the following order:  2 
sheets filter paper, 0.8% agarose gel, supported nitrocellulose (presoaked in 20X 
SSC), 2 sheets filter paper, flat fold paper towels.  Each layer was added to the stack 
and air bubbles removed from between layers by rolling with a glass rod.  A light 
weight was placed on top of the stack and allowed to transfer via capillary action 
overnight (figure 3). 
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Figure 3.  Building a Southern blot  
 
 
 3.2.6.4  Fixation on solid support 
 
Fixation of DNA onto supported nitrocellulose was done with a UV Stratalinker 2400 
(Stratagene).  Each blot, still moist with SSC from the transfer to solid support, was 
stratalinked at 1200 J/cm2. 
 
 
3.2.6.5  Radiolabeling of probes 
 
Circular DNA vectors containing the probes were digested with appropriate restriction 
enzymes to release the double stranded DNA.  Digestions were run on a 0.8 – 1.2% 
agarose gel and the correct size DNA was isolated and quantified (see section 
3.2.7.2/3). 
 
Radiolabeling of probes was carried out with the Random primed radiolabeling kit 
(Roche, 1004760).  100 ng of double stranded DNA was mixed with bi-distilled water 
to a volume of 9 µl, boiled for 5 minutes then placed on ice.  DNA was centrifuged 
briefly and mixed with 1µl each of dATP, dGTP, dTTP and 2 µl of hexanucleotide 
primer mix.  Five microliters (50 µCi) dCTP was added, then mixed with 1 µl Klenow 
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enzyme.  The reaction mixture was briefly vortexed, centrifuged, then incubated 1 
hour at 37°C.  The reaction was stopped with the addition of 2 µl of 0.2 M EDTA 
pH8.0.  The mixture was then brought to 100 µl with 78 µl TE pH8.0. 
 
A G-50 Sephadex column was prepared by placing two circles of 3M Whatman filter 
in a 1 milliliter insulin syringe followed by pre-soaked G-50 Sephadex(Pharmacia 
Biotech).  The column was centrifuged 2 minutes at 2000 X G at 25°C.  Sephadex 
was added without introducing air bubbles and centrifuged until a dry volume of 1 ml 
was achieved.   
The 100 µl of reaction mixture was added to the sephadex column and centrifuged 5 
minutes at 2000X G and 25°C.  The radio-labeled probe (in the flowthrough) was 
collected into a fresh eppendorf and the column disposed of.  The probe’s activity was 
measured in a Packard Tricarb 5430 counter using 2 µl of probe in 10 ml of 
scintillation fluid (Quickszint 212, Zinsser Analytic, Frankfurt).  Probes with activity 
of more than 400k counts per µl were considered acceptable. 
 
3.2.6.6  Hybridization, washing and signal detection 
 
Blots on nitrocellulose were rolled and placed in hybridization tubes with 20 ml 
hybridization juice and incubated at 42°C for 2 hours. 
 
500 µl of Herring Sperm genomic DNA (SSDNA, Sigma) was denatured at 100°C for 
10 minutes then placed on ice in a 50 ml Falcon tube.  Radio-labeled probe (1 million 
counts per milliliter hybridization juice) was added to the ssDNA on ice.  Fifty 
microliters of 10N NaOH was added and mixed by swirling at room temperature.  300 
µl 2 M Tris-HCl (pH 8.0) was added and mixed by swirling, then 475 µl of 1 M HCl  
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was added drop-wise while swirling to prevent precipitating out of solution.  
Denatured probe was then added to 20 ml hybridization solution, mixed and used to 
replace the pre-hybridization solution.  Blots were incubated overnight at 42°C for a 
minimum of 16 hours. 
 
Hybridization solution was removed the following day and washed with agitation 30 
minutes at 37°C in 2X SSC, 0.1% SDS, followed by 30 minutes of agitation in 0.5X 
SSC, 0.1% SDS at 50°C. 
 
Blots were placed on Polytrap 295 PE paper covered with plastic wrap, a Goligo 
autoradiography Marker (Stratagene) applied and exposed to BioMax MS or X-Omat 
film (Kodak) for 1 to 3 days at -80°C.  Films were then processed in an Agfa Curix 
HT 330U film developer.  The Goligo markers were matched from the films to the 
blots and the lanes marked.  Size of bands was determined by comparison to the 
metric ruler in the transillumination image of the gel. 
 
 
 
 
3.2.7  Northern Blotting and hybridization 
 
3.2.7.1  RNA extraction 
 
RNA extraction from tissues and cell cultures was carried out using Trizol 
(Invitrogen) following the manufactures recommended protocol, briefly described 
here. 
 
Tissues were taken from animals, frozen in liquid nitrogen and stored at -80°C.  200 
mg of tissue was placed in 2 ml Trizol and homogenized using a Polytron 
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homogenizer (Brinkmann).  Cells grown in 6 cm diameter dishes in monolayer were 
lysed directly in the dish using 2 ml Trizol and a cell scraper.  Cell lysate was 
homogenized by passing the lysate through a 1 ml pipet tip.   Homogenized sample 
was incubated for 5 minutes at room temperature.  0.4 ml chloroform was added and 
mixed by vigorous shaking.  Samples were incubated for 2 minutes at room 
temperature then centrifuged at 12000 X g for 15 minutes at 4°C.  The colorless upper 
aqueous layer was removed to a clean tube.  RNA was precipitated from the aqueous 
layer by the addition of 1 milliliter of isopropyl alcohol and incubation for 10 minutes 
at room temperature.  Sample was centrifuged at 12000 X g for 10 minutes at 4°C.  
Pellet was then washed with 2 ml of 70% ethanol and centrifuged at 7500 X g for 5 
minutes at 4°C.  Pellet was air dried for 10 minutes and dissolved in 200 µl DEPC 
treated bi-distilled water.  RNA was quantified as described in 3.2.1.6 and stored at -
80°C. 
 
3.2.7.2  Glyoxal Northern gel 
 
Ten µg of RNA was concentrated using a speedvac to a volume of 6 µl, mixed with 20 
µl of Glyoxal mix and incubated for 1 hour at 55°C then placed on ice.  A 1.2% BPTE 
agarose gel was made by boiling 1.2 g RNase free agarose in 100 ml of 1X BPTE, 
cooling and pouring into a gel form at 50°C, adding a comb, then allowing to solidify.  
The gel was place in an electrophoresis chamber covered with 1X BPTE buffer, comb 
removed and the samples loaded into wells.  The gel was then electrophoresised at 
100V (5 V/cm gel) at 4°C for 3.5 hours (method adapted from Chomczynskiand 
Sacchi, 1986).  The gel was visualized on a UV transilluminator and position of 28S 
and 18S bands noted. 
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3.2.7.3  Transfer to solid support 
 
A gel sandwich was then created by overlapping 2 sheets filter paper (Whatman 3mm) 
into 10X SSC buffer.  Gel sized layers were then placed on top of the first overlapping 
pieces of filter paper in the following order:  2 sheets filter paper, 1.2% agarose gel, 
nylon membrane (presoaked in bi-distilled water then 10X SSC), 2 sheets filter paper, 
flat fold paper towels.  Each layer was added to the stack and air bubbles removed 
from between layers by rolling with a glass rod.  A light weight was placed on top of 
the stack and the RNA transferred via capillary action overnight. 
 
3.2.7.4  Fixation onto solid support 
 
Fixation of DNA onto supported nitrocellulose was done with a UV stratalinker 
(Stratagene).  The nylon membrane was soaked for 5 minutes in 0.5 M NaOAc 
containing Methyl Blue to visualize the bands.  28S and 18S bands were marked with 
pencil and the membrane was stratalinked at 1200 J/cm2 in a Stratalinker 2400. 
 
3.2.7.5  Radiolabeling of probes 
 
Circular DNA vectors containing the probes were digested with appropriate restriction 
enzymes to release the double stranded DNA.  Digestions were run on a 0.8 – 1.2% 
agarose gel and the correct size DNA was isolated and quantified (see section 
3.2.7.2/3). 
 
Radiolabeling of probes was carried out with the Random primed radiolabeling kit 
(Roche, 1004760).  100 ng of double stranded DNA was mixed with bi-distilled water 
to a volume of 9 µl, boiled for 5 minutes then placed on ice.  DNA was centrifuged 
briefly and mixed with 1 µl each of dATP, dGTP, dTTP, 2 µl of hexanucleotide 
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primer, 5 µl (50 µCi) dCTP and 1 µl Klenow enzyme.  The reaction mixture was 
briefly vortexed then incubated for 1 hour at 37°C.  The reaction was stopped with the 
addition of 2 µl of 0.2 M EDTA pH8.0.  The mixture was then brought to 100 µl with 
78 µl TE pH8.0. 
 
A G-50 Sephadex column was created by placing two circles of 3M Whatman filter in 
a 1 ml insulin syringe followed by pre-soaked G-50 Sephadex (Pharmacia Biotech).  
The column was centrifuged 2 minutes at 2000X G and 25°C.  Sephadex was added 
without introducing air bubbles and centrifuged, then more sephadex added, until a 
dry volume of 1 ml was achieved.   
 
The 100 µl of reaction mixture was added to the sephadex column and centrifuged 5 
minutes at 25°C and 2000X G.  The radiolabeled probe was collected into a fresh 
eppendorf and the column disposed of.  The probes activity was measured in a 
Packard Tricarb 5430 counter using 2 µl of probe in 10 ml of scintillation fluid 
(Quickzint 212 Zinsser Analytic) Probes with activity of more than 4X105 counts per 
microliter were considered acceptable. 
 
3.2.7.6  Hybridization, washing and signal detection  
 
Membranes were pre-hybridized for 2 hours in church buffer at 60°C in glass roller 
tubes.  500 µl of ssDNA was denatured 10 minutes at 100°C then placed on ice in a 50 
ml Falcon tube.  Radiolabeled probe (1 million counts per milliliter hybridization 
juice) was added to the ssDNA on ice.  Fifty microliters of 10N NaOH was added and 
mixed by swirling.  300 µl 2 M Tris-HCl pH 8.0 was added and mixed by swirling, 
then 475 µl of 1 M HCl  was added drop-wise while swirling to prevent precipitating 
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out of solution.  Denatured probe was then added to 20 ml of pre-warmed church 
buffer.  Hybridization buffer with radiolabeled probe then replaced the pre-
hybridization buffer and the membrane incubated overnight (minimum of 16 hours) at 
60°C.  Tubes were rolled throughout hybridization to insure even distribution of probe 
over the membrane. 
 
The following day the membrane was removed from the hybridization tube and 
washed for 20 minutes in Church wash Solution at 50°C.  Blots were then measured 
for background activity with a hand-held Geiger counter and washed an additional ten 
minutes when required due to high background counts.  Blots were then placed on 
Polytrap 295 SE paper covered with plastic wrap, a goligo autoradiography marker 
(Stratagene) added, then exposed for 1 to 5 days to BioMax MS film (Kodak) at -
80°C.  Films were processed in an Agfa Curix HT 330U developer, the Goligo 
autoradiography markers matched and the lanes marked. 
 
 
3.2.8  In Situ hybridization 
 
3.2.8.1  Preparation of probe 
 
The plasmid containing the probe was linearized with the appropriate restriction 
endonuclease.  Ten micrograms DNA, 4 µl 10X RE buffer, 4 µl 10X BSA (if needed) 
and 40-200 units RE were mixed and the volume brought to 40 µl with nuclease free 
water.  The digestion was incubated 2-3 hours at the manufacturers recommended 
temperature for the RE.  The digestion volume was brought to 100 µl with bi-distilled 
water then 100 µl phenol/chloroform added and mixed by shaking.  The mixture was 
centrifuged 2 minutes at14000 rpm and the upper aqueous phase transferred to a fresh 
eppendorf.  DNA was then precipitated by adding 10 µl 3 M NaAc pH 5.2, 250 µl 
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cold 100% EtOH and incubating 30 minutes at -20°C.  The precipitate was 
centrifuged for 10 minutes at 4°C and 14000 rpm, the supernatant removed and the 
pellet washed once with 1 ml of cold 70% EtOH.  The pellet was air dried, 
resuspended in 10 µl nuclease free water, the concentration determined (see section 
3.2.1.6) and stored with a final concentration of 1 µg/µl at -80°C. 
 
3.2.8.2   Radiolabeling 
 
 
Gemini transcription kits (Promega) were used for radiolabeling of probes as 
recommended by the manufacturer and briefly described here.   
A reaction mixture was created by mixing 2 µl 5X transcription buffer, 1 µl 100 mM 
DTT, 0.5 µl rATP, 0.5 µl rCTP, 0.5 µl rGTP, 3 µl (25 µCi/µl) 35S-UTP, 0.5 µl RNasin, 
1 µl 1 µg/µl linerized plasmid, and 1 µl plasmid dependant polymerase.  The reaction 
mixture was vortexed, centrifuged briefly, then incubated for 1 hour at 37°C followed 
by a brief centrifugation.  An additional 1 µl of polymerase was added and incubated 
again for1 hour more followed by a brief centrifugation.  0.5 µl RNasin and 0.5 µl 
DNase were added then vortexed, centrifuged and incubated 15 minutes at 37°C.  The 
reaction mixture was then centrifuged and stored on ice.   
 
Unincorporated nucleotides were removed by running through a Nuctrap column 
(Stratagene #400702).  Seven microliters 0.5 M EDTA, 14 µl 5X NTE (100 mM 
Tris(pH 7.5), 500 mM NaCl, 50 mM EDTA), 38 µl H2O were added to the reaction 
mixture.  Seventy microliters of NTE were added to the column and pushed through.  
The reaction mixture was then applied to the column and pushed through into a fresh 
eppendorf.  Seventy microliters NTE was applied a second time to the column and 
pushed through into the same eppendorf.  Total elutant collected was approximately 
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100 µl.  One microliter of labeled probe was measured in a beta counter (Packard 
Tricarb 5430).  Probes of 1 X 106 counts /µl were aliquoted into 50 µl samples and 
frozen for later use. 
 
 
3.2.8.3  Hybridization, washing and visualization 
 
100 µl of complete hybridization solution was used per slide.  Complete hybridization 
solution was prepared as follows: 
Five microliters radiolabeled probe (1 X 106 counts /µl) were denatured for 3 minutes 
at 85°C then placed on ice.  The probe and 5 µl 1M DTT were added to 100 µl 85°C 
pre-heated In situ hybridization solution.  
 
Slides to be hybridized were placed on trays in a moisture chamber with hybridization 
solution in the bottom section.  100 µl of complete hybridization solution was dropped 
onto each section and covered with a square of parafilm M.  The chamber was closed 
and incubated overnight at 50°C  
 
Hybridized slides were washed in baths the following day (without allowing them to 
dry out at any time) as follows: 
20 minutes 50°C 5X SSC, remove parafilm M, 30 minutes 50°C 2X SSC/50% 
formamide, 10mins 37°C 1X TNE, 30 minutes 37°C 1X TNE /10 µg/ml RNase A, 10 
minutes 37°C 1X TNE, 20 minutes 50°C 2X SSC, 20 minutes 50°C 0.2X SSC, 20 
minutes 50°C 0.2X SSC, 5 minutes room temperature 70%EtOH, 5 minutes room 
temperature 95% EtOH and air dry.  Slides were exposed overnight to BioMax MR 
film, the film developed and development time for the emulsion decided.   
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3.2.8.4  Emulsion and development  
 
Slides were dipped in Kodak autoradiography emulsion NTB2 as follows (all 
handling of emulsion was carried out in absolute dark): 
 
  Approximately 30 ml of NTB2 emulsion was melted in a falcon tube using a water 
bath at 45°C.  Twenty milliliters of 2%glycerol was preheated to 45°C and a water 
bath, with magnetic stirring, preheated to 50°C.  The emulsion was added slowly to 
the glycerol and mixed without creating air bubbles then poured into a slide dipping 
vessel in the 50°C water bath.  A blank slide was first dipped to verify no air bubbles 
were in the emulsion.  Slides with hybridized sections were then dipped three times 
into the emulsion and placed vertically in a drying rack with the frosted writing 
surface facing down.  Slides were allowed to dry for 1 hour then placed in light tight 
containers with desiccant and sealed.  Slides were stored at 4°C until developed.  
 
Slides were developed by incubating 2 minutes in Kodak D-76 developer (6.8 mg/ml), 
dipping briefly in water, incubating 4 minutes in Kodak fixer (18 mg/ml), dipping 
briefly in water and allowing to dry.  Emulsion was removed from the back side of the 
slides and sections were coverslipped. 
 
3.2.9 Phenotypical analysis of transgenic animals 
 
 
3.2.9.1  Metabolic cages for urine collection 
 
Mice were placed in stainless steel metabolic cages from 17:00 to 10:00 the next day, 
with free access to water but no food.  Overnight urine was collected in 15 ml falcon 
tubes.  Urine was frozen for later analysis (sect. 3.2.9.3). 
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3.2.9.2  Necropsy and sample collection 
 
Animals were anesthetized by peritoneal injection of  ketamine/xylazine (70/7 
mg/kg).  One heparinized capillary was filled with ~100 µl blood from the retro-
orbital venous plexus and analyzed in an AVL 9180 (AVL Medizintechnik GmbH) 
electrolyte analyzer for serum Na, K and Ca levels.  Remaining blood was taken from 
the vena cava, incubated for 1 hour at 30°C then further processed (see sect. 3.2.9.3).  
Samples of liver, kidney, spleen, heart and lung were removed and placed in 4% 
paraformaldehyde for fixation and sectioning.  The left femur was removed and 
cleaned for peripheral quantitative computed tomography (pCQT) bone densitometry 
analysis.  The left tibia was removed, cleaned and snap frozen in liquid nitrogen then 
stored at -80°C for RNA preparation.  The right femur was removed and cleaned for 
MMA embedding and sectioning.  The first lumbar vertebra was removed and cleaned 
for MMA embedding and sectioning.  The remaining spinal column was removed and 
placed in 70% EtOH for bone densitometry analysis. 
 
 
3.2.9.3  Serum and urine analysis 
 
Two dilutions of urine were prepared for analysis.  Dilution A consisted of 125 µl of 
urine diluted with 125 µl of 2N HCl for analysis by flame photometry in an EFOX 
5053 (Eppendorf, Hamburg, Germany).  Dilution B consisted of 30 µl of Dilution A 
mixed with 300 µl bi-distilled water for analysis in Hitachi 766 autoanalyzer 
(Boehringer Mannheim, Mannheim, Germany) for ion content analysis.  Serum was 
diluted 1:2 for analysis in the same equipment as the urine samples. 
 
Urine samples were analyzed for sodium, potassium, calcium, phosphate and 
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creatinine.  Serum samples were analyzed for sodium, potassium, calcium, alkaline 
phosphatase, GOT, HAST, CK, t-billirubin, albumin, creatinine, phosphate, PTH, and 
osteocalcin. 1,25(OH)2 vitamin D3  was measured by Immudiagnostik AG (Belisheim, 
Germany). 
  
3.2.9.4  PTH ELISA  
 
Serum levels of intact PTH (1-84) were measured using the Rat intact PTH ELISA kit 
(Immutopics).  The manufacturer’s recommended protocol was used and is briefly 
described here.  In duplicate twenty five microliters of sample were loaded into a 
streptavadin coated microtiter plate with the provided rat intact PTH standards and 
controls.  100 µl of working antibody solution (1:1 mixture of rat biotinylated 
antibody with rat HRP conjugated antibody) were added to each well, the plate sealed 
and covered with aluminum foil.  The plate was incubated for three hours at room 
temperature with constant shaking.  The plate was unsealed, the contents of each well 
aspirated, then washed five times with the provided working wash solution with the 
final wash being aspirated.  150 µl of ELISA HRP substrate were aded to each well, 
the plate seasled and covered with aluminum foil and incubated 30 minutes at room 
temperature with constant shaking.  The plate was unsealed and the 595nm 
absorbance was read from each well within 5 minutes using the 0 pg/ml standard 
wells as a blank.  100 µl of ELISA stop solution was added to the wells and the 450 
nm absorbance was read within ten minutes using 150 µl of substrate and 100 µl of 
stop solution as a reagent blank.  For PTH values that fell within 0 to 800 pg/ml the 
450 nm absorbance was used to determine concentration.  The corrected absorbance 
was calculated by subtracting the 0 pg/ml standard levels from all other OD values.  
The corrected absorbance was plotted on a log-log graph against the concentration 
and unknown values determined by linear regression analysis.   
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3.2.9.5 Osteocalcin measurement 
Serum osteocalcin was analyzed using a mouse osteocalcin IRMA kit 
(Immundiagnostik, Bensheim Germany).  The manufactures protocol was followed 
and is briefly described here.  Standards provided were dissolved in one milliliter bi-
distilled water.  Ten microliters of the controls and samples were diluted with 100 µl 
zero standard.  Twenty five microliters of samples, controls and standards were 
aliquoted into eppendorf tubes and 200 µl I125 labeled osteocalcin antibody added and 
vortexed.  One bead was added to each reaction mixture and allowed to incubate for 
24 hours.  Wash solution was diluted from stock and allowed to equilibrate overnight 
at room temperature.  After 24 hour incubation the supernatant was removed and 
washed three times with 2 ml wash solution.  Beads were then measured using a 
gamma counter.  Sample values were calculated from the standard curve generated.  
 
3.2.10 Histology 
3.2.10.1 Paraffin embedding 
 
Tissues harvested from animals were placed in embedding cassettes and fixed for 24 
hours in 4% paraformaldehyde at 4°C, washed overnight in 0.1 M phosphate buffer, 
then placed in 70% ethanol.  Tissues were processed in a Hypercenter 2 (Shandon) 
and embedded using a Tissue-TEKII tissue embedding center (Ames). 
 
 
3.2.10.2 Methylacrylate embedding 
 
3.2.10.2.1 Fixation and preparation 
 
After fixation for 24 hours in 4% paraformaldehyde, the tissues were washed for 24 
hours in 0.1 M phosphate buffer with 10% sucrose added at 4°C with stirring and one 
change of buffer.  Tissues were then placed in a container that allowed for a magnetic 
3. Materials and Methods 
 
 50
stirrer and were kept at 4°C while in solutions.  The specimens were processed 2 days 
in 70% EtOH, 2 days in 95% EtOH, 2 days in 100% isopropanol (changed once), 2 
days in xylene (solution changed once), 2 days in MMA I, 2 days in MMA II, 2 days 
in MMA III (Erben, 1997). 
 
3.2.10.2.2 Embedding 
 
Immunohistochemical 
 
The tissues were embedded in round glass vials 2.5 cm in diameter and 6 cm in height 
with MMA polymerization mixture II precast in the bottom.  The embedding vials 
were kept cold at all times during the embedding process.  Vials were filled with 
MMA polymerization mixture I, tissues were placed against the hardened bottom, 
vials sealed and placed in a climate chamber at -20°C to polymerize. Once 
polymerized, the glass vials were broken and the blocks trimmed for sectioning. 
 
3.2.10.3 Slide preparation and Sectioning 
 
Slides used for sections were first cleaned in acetone for 10 minutes at room 
temperature, rinsed with water, incubated 5 minutes in acetone followed by 5 minutes 
incubation in (3-Aminopropyl)triethoxysilane (APES) solution.  Slides were then 
washed twice in bi-distilled water then air dried at 50°C.  Slides were stored at room 
temperature. Sections were cut with a Microm HM 355 rotation microtome.  Paraffin 
sections were cut with a thickness of 8 µm and methylacrylate sections were prepared 
with a thickness of 4 µm.   
  
Deplasticization 
 
Slides were placed in 3 successive solutions of methoxyethylacetate, 20 minutes per 
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solution.  Methoxyethylacetate was changed after processing 40 slides.  Slides were 
washed twice for 5 minutes in acetone then washed twice for 5 minutes in bi-distilled 
water. 
 
Deparaffinization 
Slides were placed in 2 successive washes of xylol for 15 minutes, 5 minutes in 100% 
EtOH, 5 minutes in 70% EtOH, 5 minutes in 40% EtOH and washed for 5 minutes in 
bi-distilled water.   
 
3.2.10.4  Staining and visualization of sections 
Hematoxylin and Eosin 
 
Slides were incubated for one minute in filtered Harris Hematoxylin then rinsed in 
flowing water until the incubation chamber had been cleared of stain.  Sections were 
then incubated one minute in 1.0% Eosin Y.  Sections were dehydrated five minutes 
in ascending alcohol solutions of 70%, 80%, 95%, and twice in 100% ethanol.  Slides 
were cleared with two series of five minutes incubation in xylene. 
 
Modified Van Kossa 
Slides were rehydrated then transferred to a solution of 1% silver nitrate for 15-60 
minutes under a strong light.  Blackening of the mineralized bone can be seen 
macroscopically.  Sections were gently washed in three successive bi-distilled water 
baths then treated with thiosulfate for 5 minutes and again rinsed well with bi-distilled 
water.  Section were counterstained for 3 minutes with methyl green, rinsed in three 
successive washed of n-butanol then either immersed in 2 successive xylol baths of 
five minutes each or further processed using the McNeal protocol.  Sections were 
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coverslipped with Roti-histokit and glass coverslip. 
 
McNeal 
Sections were immersed in bi-distilled water instead of xylol after counterstaining in 
the Von Kossa staining protocol.  Slides were immersed for 20 to 60 minutes in 
freshly prepared 5% tetrachrome then rinsed twice in bi-distilled water, briefly rinsed 
twice in 2-propanol, then soaked 5 minutes in xylol and finally coverslipped with 
Roti-histokit and glass coverslip. 
 
Visualization 
Sections were visualized using a Zeiss axioskop microscope (Carl Zeiss Mikroscopie, 
Berlin Germany) and images captured using a Spot Diagnostic inc. model 1.3.0 digital 
image capture devise (Visitron Systems, Puchheim Germany) and Adobe Photoshop 
software. 
 
 
3.2.11 Peripheral quantitative computed tomography 
 
Left femurs were excised during necropsy, fixed and stored in 70% ethanol for a 
minimum of two weeks.  Four slices from each femur were analyzed by peripheral 
quantitative computed tomography (pQCT) (Statech Medizintechnik, Pforzheim 
Germany).  Three slices were within the distal femoral metaphysis and the fourth was 
at mid-diaphysis. (Figure 4) 
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Figure 4 
 
Definition of slices measured for densitometry. 
3 distal femur measurements and one mid-diaphysis 
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4 Results 
 
4.1 Assay for competent transgenic constructs 
 
4.1.1 Blueprints of transgenes 
 
 
Osteocalcin-hPHEX (figure 5)  
 
The 2.4kb hPHEX coding sequence was ligated in a three way ligation with pCDNA I 
(Invitrogen) and the Osteocalcin (OPG2) promoter (gift from Dr. Karsenty). 
 
pCDNA I   Xho I / Bam HI   4.1 Kb 
OPG2 Promoter  Bam HI / Hind III (blunt)  1.3 Kb 
hPHEX cDNA Sma I / Xho I   2.4 Kb 
 
 
ß-actin hPHEX (figure 5) 
 
Multiple cloning steps were used to create a final plasmid containing the following 
fragments: 
 
β-actin promoter Hind III(blunted) / SalI(blunted) 4.0 Kb 
hPHEX cDNA Sma I / Xho I   2.4 Kb 
pCDNA I   Xho I / Bam HI   4.0 Kb 
pBluescript  Bam HI / EcoRV   30  bp 
 
Both constructs contain an SV40 polyadenylation site from the plasmid pCDNA I 
(Invitrogen).  This commercial plasmid contains an intronic sequence of 70bp.  The 
use of this intronic sequence permits RNA transcribed from the transgene to be 
distinguished from endogenous mPHEX, which has high nucleotide similarity. 
 
The OG2-hPHEX transgene was digested with Kpn I to verify the expected DNA 
sizes of 4.66Kb and 3.23Kb.  The β-actin-hPHEX transgene was digested with Kpn I 
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to verify fragment sizes of 7.4 and 3.0. Both 
transgenes were sequenced to verify correct 
orientation of all fragments and subcloning 
junctions’ integrity.   
 
 
4.1.2 Assay for in vitro expression 
 
Once the transgene constructs were verified, 
they were subjected to TnT Quick Coupled 
transcription and translation (Promega) 
reactions.  One microliter of reaction sample 
was used for western analysis.  A primary band 
was seen at 125 kDa in both constructs indicating a 
Figure 5 
Transgene constructs for osteocalcin – hPHEX and β-actin – hPHEX showing hybridization probe 
for southern blots. 
4.0 Kb 2393 bp 952 bp
b-actin
promoter hPHEX cDNA
pCDNA1
poly adenylation
 site
Hind III
blunted
Kpn IXba IBam HIBam HI
Probe to 
check for 
integration
1.3 Kb 2393 bp 952 bp
osteocalcin
promoter hPHEX cDNA
pCDNA1
poly adenylation
 site
Bam HI
Kpn I
Xba IBam HIBam HI
Probe to 
check for 
integration
Figure 6 
TnT Quick Transcription 
Translation of OG2-
hPHEX and β-actin-
hPHEX constructs 
4. Results 
 
 
 56
primary transcription start site.   
Also seen were multiple smaller bands 
indicating alternate transcription start sites, or 
possible translational proteolytic cleavage 
products.  An artifact band for globin appeared 
in both samples in the lower kDa range that has 
been previously report with this system (figure 
6). 
 
4.1.3 Assay for in vivo expression 
The OG2-PHEX transgene was transiently 
transfected into COS-7 cells, incubated 48 
hours at 37°C and total RNA prepared.  Total RNA 
and the plasmid transgene were treated to RT-PCR 
using the primers pCDNA – AS Intron and PHEX2 
for 30 cycles.  Genomic DNA produced a band of 
521bp and the mRNA, due to an intron within the 
PCR amplified region, was 451bp.  The plasmid 
DNA produced a single band of 521bp, and the 
mRNA from the transient transfection produced 
bands of 521bp and 451bp (figure 7). 
 
One microgram each of the OG2-hPHEX and β-actin-
hPHEX transgene constructs were transiently transfected 
Figure 8 
Northern of transient 
transfected COS-7 
cells 
Figure 7 
PCR of OG2-hPHEX transgene and 
reverse transcribed RNA from 
transiently transfected COS-7 cells. 
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into COS-7 cells while an equal amount of pCDNA1 was transfected as a negative 
control.  The cells were allowed to express for 48 hours then the monolayer cells were 
harvested and total RNA prepared using Trizol.  Six micrograms of total RNA were 
used in a glyoxal Northern.  The RNA was incubated overnight in Church buffer at 
55°C using the radiolabeled 1.57Kb BamHI fragment of hPHEX as a probe.  The blot 
was exposed to BioMax film for 24 hours at -80°C, allowed to thaw to room 
temperature and developed.  The pCDNA1 RNA showed no hybridization while the 
OG2-hPHEX produced bands of 6.0 and 3.4 Kb .  The β-actin-hPHEX hybridized 
with the probe at 8.0, 4.0 and 3.5 Kb (figure 8). 
 
4.1.4  In situ Hybridization visualization 
 
 
Figure 9  In situ hybridization of mouse tibia. 
2.5X  A) light field and B) dark field microscopy.   
 
In situ hybridization was carried out using a probe consisting of exons 9 to 19 of the 
mPHEX gene. Positive expression is most clearly seen in the dark field microscopy 
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image (figure 9, arrows).  Expression is localized to trabecular and cortical bone.  
These results clearly indicate that hPHEX if overexpressed specifically in bone or 
overexpressed ubiquitously could be identified through in situ hybridization.  In situ 
hybridization of hPHEX transgenic mice did not show any appreciable difference to 
wild-type sections (data not shown).  
 
4.2 Confirmation of germline transmission 
 (First Pronuclear Injection) 
RCC Ltd, (Füllinsdorf, Switzerland) was contracted to perform the 
pronuclear injections of the OG2-hPHEX transgene and return 3 
transgenic animals without clause for expression of the transgene.  
Two lines of mice were established by Rcc Ltd. with a third being 
too sick for further breeding.  The lines designated 47 and 79 were 
subjected to Southern blot analysis to ensure the germ-line 
transmission of the transgene to offspring.  Lineage 47 displayed a 
major band at 3.0Kb and a single band at 8.2Kb.  Lineage 79 
displayed a major band also at 3.0Kb and minor bands at 4.6Kb and 
4.9Kb (figure 10).   
 
Mice from both lineages were sacrifice and tissues removed for total 
RNA extraction.  Total RNA was used for RT-PCR (64°C, 30 cycles) to determine 
expression of the hPHEX transgene, using primers pCDNA – AS Intron and PHEX2.  
As control, osteocalcin primers were used in a PCR of the same reverse transcription 
reaction.  Bands of 521bp, indicative of genomic DNA, were seen for the transgenic 
animals from both lineages but not for the WT littermates, no bands of 451bp, 
Figure 10 
Southern of 
lineage 47 and 79. 
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indicative of RNA were seen for any of the animals.  (figure 11) 
 
 
Northern blot analysis was carried out on different mice from both lineages.  Calvaria 
and femur were extracted from mice, snap frozen in liquid nitrogen and used for total 
RNA preparations.  Five micrograms of total RNA was used for each tissue type from 
each animal.  The RNA was hybridized overnight in Church buffer at 55°C using the 
radiolabeled 1.57Kb BamHI fragment of hPHEX as a probe.  No hybridization bands 
were seen for any of the samples. 
 
From the analysis of the Southern, Northern and RT-PCR from the two lineages of 
mice provided by RCC Ltd., we  concluded that there was no expression of the 
hPHEX mRNA or protein.  Without expression of the mRNA there was no possibility 
of examining our hypothesis.  
 
4.3 Confirmation of germline transmission 
 (Second pronuclear injections) 
The OG2-hPHEX transgene and the β-actin-hPHEX transgene were sent to Dr. 
Harold Jueppner (Harvard Medical School, Boston) for a second attempt at pro-
Figure 11 
RT-PCR of lineage 47 and 79 
mice for OG2-hPHEX 
transgene with control PCR 
from same RT reaction for 
osteocalcin 
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nuclear injection, in order to create transgenic mice that expressed the hPHEX 
protein. Two lines of mice with the β-actin-hPHEX transgene and a single line of 
OG2-hPHEX transgenic mice were created.   
To determine whether the transgene was transmitted to offspring, a PCR using 
primers pCDNA – AS Intron and PHEX2 was performed (64°C, 30 cycles).  The mice 
from all lineages show a single band at 521bp if they are positive for the transgene 
and no band if the transgene has not been transmitted (i.e. WT mice) (figure 12). 
   
 
In order to see the copy number and number of transgene integration sites, a southern 
blot analysis was run using the Xba I / Kpn I probe on all transgenic lineages returned.  
OG2-hPHEX produced a transgenic mouse with four integration sites.  One 
integration site at 2.8Kb contained a markedly greater number of construct copies than 
the other three sites at 3.3Kb, 4.0Kb and 6.4Kb.  The first β-actin-hPHEX transgenic 
lineage, designated β-actin 236, displayed a doublet on southern blot analysis at 
2.0Kb and 5.6Kb.  The second β-actin-hPHEX lineage, designated β-actin 237, 
showed a single band at 6.4Kb.  The β-actin 237 lineage probably has a greater copy 
number at the integration site compared to the two integration sites of the β-actin 236 
lineage (figure 13). 
Figure 12 
PCR for hPHEX 
transmission to 
offspring using 
PEX2 and 
pCDNA AS 
Intron 
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4.3.1 Distribution of tissue expression 
RT-PCR was used to determine expression of the transgene in different tissues.  Total 
RNA from liver and skin from β-actin-hPHEX lineages and calvaria and femur from 
OG2-hPHEX was produced using Trizol extraction.  PCR of the reverse transcribed 
DNA was carried out at 64°C for 30 cycles using primers PHEX2 and pCDNA AS 
Intron.  Wild-type littermates were used as negative controls.  The negative controls 
showed no bands at all, while the OG2-hPHEX lineage displayed a band at 521bp 
corresponding to genomic DNA.  β-actin-hPHEX 237 and β-actin-hPHEX 236 liver 
Figure 13 
Southern blot analysis of OG2-hPHEX and β-actin-hPHEX transgenic lineages with 
corresponding Wild-type littermates. 
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and skin samples displayed bands at 521 and 451 corresponding to DNA and mRNA 
bands.  The skin sample of β-actin-hPHEX 236 and both samples of the β-actin-
hPHEX 237 lineage displayed a lighter band at 451bp than the β-actin-hPHEX 236 
liver (figure 14).   
 
 
 
 
In order to determine if the 451bp band was due to the presence of the hPHEX 
transgene the PCR was repeated for the β-actin-hPHEX 236 liver sample.  PCR using 
the same primers was run with material from the reverse transcription reaction side by 
side with the material from the total RNA preparation.  The RT-PCR product was 
digested with XbaI.  The genomic DNA product was cut into bands of 301bp and 
220bp.  The mRNA product was digested to bands of 301bp and 150bp.  A large band 
was seen for the cleaved 301bp band present in both species, while the 220 and 150bp 
bands are present but weaker (figure 15).  
 
 
Figure 14  RT-PCR of  transgenic lineages.  Genomic DNA 521bp, mRNA 451bp 
4. Results 
 
 
 63
 
 
 
 
Northern Blot Analysis 
Northern blot analysis was used on total RNA from liver, kidney, and bone with 
exposure times up to four weeks on Kodak BioMax MS film.  No distinguishable 
bands were seen when using the full length hPHEX cDNA as a radiolabeled probe. 
 
Figure 15 
β-actin-hPHEX 236 liver. 
 
a) PCR of RT and total RNA.   b) XbaI digestion of RT-PCR. 
A
B
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4.4 Assay of biochemical parameters 
The disease XLH and its mouse homologue, Hyp, present in the same manner. 
Abnormalities in the biochemical state of many measurable parameters in the affected 
individual are readily apparent.  We measured the values for the following 
parameters: body weight, serum values for calcium, potassium, sodium, GOT, 
alkaline phosphatase, creatine kinase, albumin, HAST, creatinine, phosphorus, 
osteocalcin, PTH, urine values for sodium, potassium, calcium, creatinine, and 
phosphorus.  Mean values for all measurements follow in the appendices.  
Significance was determined through unpaired t-test for comparison of two groups 
and ANOVA for groups of three test subjects (Minitab statistical software) 
 
4.4.1  Serum phosphate levels remain unchanged in β-actin - hPHEX mice 
236 β-actin hPHEX 
Female animals from the β-actin 236 lineage were sacrificed at 12 weeks of age and 
samples taken as described in methods.  A p value of  > .05 shows there is no 
Figure 16 
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Comparison of  β-actin 236  transgenic 
and wild-type serum values.   
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significant difference between body weight in the transgenic β-actin 236 and wild-
type mice (figure 16).  Further comparison of the ion concentrations from AVL and 
normal serum tests demonstrate unchanged values between groups (figure 17).   
 
 
 
 
 
A primary attribute of the Hyp mice is the depressed levels of serum phosphate.  As 
indicated by the results in figure 18, the phosphate levels remain unaffected in the β-
actin 236 transgenic mice in relationship to wild-type mice.  There is a large 
difference seen in the PTH levels between groups but the large standard of deviation 
and a p value of more than 0.05 indicate the results are not significant.  In the analysis 
of all biochemical parameters examined for the β-actin 236 female transgenic mice 
there were no significant differences compared to wild-type mice (tables 1 – 3). 
 
Qui et. al. were able to establish there is no gender dependent effect of the PHEX 
gene.  In order to confirm this and confirm no gender effects of the β-actin hPHEX 
transgene, male and female mice of the 237 lineage were analyzed for the same 
Figure 18 
Comparison of  β-actin 
236  transgenic and 
wild-type serum 
values 
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biochemical parameters.  Body weight of both genders remained constant between 
transgenic and wild-type animals (figure 19).  Blood drawn by retro-orbital puncture 
at the time of animal sacrifice as well cardiac serum samples displayed no significant 
differences in calcium or potassium values (figure 20).   
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Figure 20 
Serum probes taken by retroorbital puncture and cardiac bleed analyzed for ion content.  
Comparison between wild-type and 237 β-actin PHEX transgenic animals for both 
genders. 
Figure 19 
Body weight of male and 
female 237 b-actin 
hPHEX mice compared 
to wild-ttype littermates/ 
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gender (figure 21: A,B,C).    
 
Overnight collections of urine were 
analyzed for ion content and displayed no 
significant variation in sodium, calcium or 
potassium, corrected by creatinine content 
(table 6).  In the overall analysis of the 237 
biochemical data, there were no significant 
changes in any of the measured  
parameters (tables 4 – 6). 
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Comparison of serum values between wild-
type and 237 β-actin PHEX transgenic 
animals for both genders. 
A) PTH 
B) Phosphorus 
C) Osteocalcin 
B 
C 
4. Results 
 
 
 68
4.4.2 Rescue mice display normalization of parameters 
In order to examine whether the expression of the transgene in varied tissues, 
including bone, could rescue the phenotypical abnormalities of the Hyp mice, a cross 
of the two lineages was established.  
Only β-actin 236 mice were used for 
crossing into the Hyp mice due to the 
higher expression of hPHEX 
compared to the β-actin 237 lineage.  
The offspring from the crossing of 
hPHEX transgenic mice and Hyp 
affected mice were labeled rescue 
mice if they carried the transgene and 
hyp mutation simultaneously.  Three 
different offspring 
combinations were possible: 
Hyp positive and hPHEX 
negative (+/-, Hyp mice), 
Hyp positive and hPHEX 
positive (+/+, rescue mice) 
or Hyp negative and hPHEX 
negative (-/-, wild-type).  
C57/Bl6 mice were used as 
control mice.  The most 
significant phenotypical or 
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Figure 22 
Rescue mice display a significant recovery of 
body weight over the hyp mutant mice. 
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cardiac puncture serum/ 
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biochemical result from the crossing of the hPHEX transgenic mice and Hyp mice, 
was the almost normalization of body weight for the rescue mice and the increase in 
bone mineral density.  
 
The rescue mice showed a recovery of seventy-one percent of lost body weight due to 
the hyp mutation.  Statistical analysis gives a p-value of less than 0.001, making the 
findings highly significant (figure 22).  In gross examination of rescue mice compared 
to hyp mice there is less extreme curvature of the spinal column, which is commonly 
seen in hyp mice.  Calcium, potassium and sodium values as measured in AVL and 
cardiac serum probes showed no significant variation.  Other unaffected parameters in 
the rescue mice were serum values for T-bili, CK, ALB and Hast, all with p-values 
greater than  0.05.  Values displaying a trend toward normalization included GOT, 
creatin, phosphate and PTH (figures 23 - 25) .  Urine values corrected by creatine 
content were not significantly different between hyp, rescue and wild-type mice 
(tables 7 – 9).   
Figure 24 
Serum phosphate levels from cardiac 
puncture. 
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Figure 25 
Serum PTH levels from cardiac puncture. 
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4.4.3 Biochemical data tables 
 β-actin-hPHEX 236 
 
BW Ca Na K
g mM mM mM
Transgenic
n= 6 6 6 6
mean 23.63 1.22 138.17 3.38
SD 1.48 0.02 2.32 0.28
Wild Type
n = 8 8 8 8
mean 23.24 1.24 140.00 3.28
SD 1.12 0.03 3.16 0.23
BW & AVL serum values for female β-actin 236
Table 1
 
  
Na K Ca AP T-Bili CK Alb HAST Crea Phos PTH OC
mM mM mM U / l µM U / l g / l mM µM mM pg / ml ng/ml
Transgenic
n= 6 6 6 6 6 6 6 6 6 6 5 6
mean 148.22 3.90 2.19 131.83 1.90 82.00 30.83 9.62 12.17 2.75 5.92 103.40
SD 1.70 0.39 0.08 15.69 0.41 31.28 1.99 1.47 1.17 0.33 3.03 17.46
Wild Type
n = 8 8 8 8 8 7 8 8 8 8 2 8
mean 146.94 3.59 2.18 133.25 1.80 92.00 31.56 9.21 11.88 2.79 2.83 112.75
SD 0.84 0.22 0.04 9.51 0.30 23.16 2.03 0.72 0.99 0.47 3.60 31.86
Serum values for female β-actin 236 
Table 2
 
Na / Crea K / Crea Ca / Crea Crea Phos / Crea
mM / mM mM / mM mM / mM mM mM / mM
Transgenic
n = 6 6 6 6 6
mean 48.04 104.57 1.29 4.29 19.63
SD 10.40 61.35 0.58 1.85 5.86
Wild type
n = 8 8 8 8 8
mean 54.26 115.49 1.49 3.97 20.86
SD 21.84 87.52 0.43 1.32 5.76
Urine values for female β-actin 236
Table 3
 
 
 
Abbreviations 
 
BW  –  Body Weight 
Ca    – Calcium 
Na    – Sodium 
K      – Potassium 
SD    – Standard deviation 
AP    – Alkaline Phosphatase 
T-bili – T billirubin 
CK    – Creatine kinase 
Alb    – Albumin 
HAST – N-hydroxyarylamine                   
.                      sulfotransferases  
Crea  – Creatinine 
Phos – Phosphorous 
OC   –  Osteocalcin
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β-actin-hPHEX 237 
 
  
Transgenic BW Ca K Transgenic BW Ca K
Male g mM mM Female g mM mM
n = 8 7 7 n = 7 7 7
mean 22.95 1.24 4.33 mean 18.02 1.26 4.03
SD 2.35 0.06 0.51 SD 1.12 0.04 0.29
Wild type
WT Male Female
n = 6 6 6 n = 3 3 3
mean 25.13 1.23 4.35 mean 20.68 1.25 4.17
SD 1.65 0.07 0.46 SD 1.05 0.03 0.23
BW & AVL serum values for β-actin 237
Table 4
 
 
 
 
 
 
 
 
 
 
Na K Ca GOT AP CK Alb HAST Crea Phos PTH OC
Trans. Male mM mM mM U / l U / l U / l g / l mM µM mM pg / ml ng/ml
n = 7 7 7 7 7 7 7 7 7 7 7 7
mean 157.01 2.23 1.12 39.71 75.57 64.00 14.60 5.18 10.29 1.42 27.35 11.16
SD 2.62 0.13 0.04 30.11 31.64 122.74 0.53 0.94 0.76 0.18 11.99 3.70
WT Male
n = 6 6 6 6 6 6 6 6 6 6 6 6
mean 156.10 2.47 1.11 25.00 60.83 27.83 13.59 4.95 10.17 1.46 32.85 12.50
SD 2.49 0.38 0.02 16.71 20.70 39.92 0.71 1.62 1.72 0.16 15.91 4.46
Trans. Female
n = 7 7 7 7 7 7 7 7 7 7 7 7
mean 157.73 2.41 1.13 30.57 77.14 16.14 16.32 4.65 12.00 1.32 13.80 13.96
SD 2.38 0.32 0.05 17.08 29.11 8.84 1.74 1.65 1.91 0.32 6.41 7.65
WT Female
n = 3 3 3 3 3 3 3 3 3 3 2 3
mean 158.47 2.31 1.07 35.00 52.67 19.33 14.93 4.72 10.00 1.20 10.39 8.13
SD 1.97 0.33 0.01 18.68 11.93 18.58 1.34 0.30 1.00 0.15 7.09 2.42
Table 5
Serum values for β-actin 237
 
 
Abbreviations 
 
BW  –  Body Weight 
Ca    – Calcium 
Na    – Sodium 
K      – Potassium 
SD    – Standard 
Deviation 
GOT –   Glutamate  
Oxaloacetate  
Transaminase 
AP    – Alkaline 
Phosphatase 
T-bili – T billirubin 
CK    – Creatine kinase 
Alb    – Albumin 
HAST – N-hydroxyarylamine  
.                      sulfotransferases  
Crea  – Creatinine 
Phos – Phosphorous 
PTH –    Parathyroid                
               hormone  
OC   –  Osteocalcin 
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β-actin-hPHEX 237 
 
 
Na / Crea K / Crea Ca / Crea Crea Phos / Crea
mM/mM mM/mM mM/mM mM mM /mM
male transgenic
n = 8 8 8 8 8
mean 39.09 47.76 1.21 4.38 21.54
SD 23.95 16.98 0.62 3.55 12.49
male wild type 
n = 6 6 6 6 6
mean 38.33 58.69 1.42 5.26 19.07
SD 20.32 22.75 0.90 4.88 13.24
female transgenic
n = 7 7 7 7 7
mean 44.73 54.84 1.77 2.36 23.77
SD 16.39 14.54 0.34 0.98 7.59
female w ild type
n = 3 3 3 3 3
mean 31.90 70.80 1.34 2.76 11.14
SD 11.17 66.51 1.59 1.21 5.52
Table 6
Urine values for β-actin 237
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Rescue Mice 
 
 
 
BW Ca K
Genotype g mM mM
Hyp
n = 4 4 4
mean 16.30 1.19 3.70
SD 1.92 0.12 0.42
rescue
n = 8 8 8
mean 22.49 1.22 4.10
SD 2.86 0.09 0.60
wild-type
n = 8 8 8
mean 24.97 1.22 4.15
SD 1.07 0.03 0.41
Table 7
BW and AVL serum values for rescue mice
 
 
 
 
 
 
 
 
Na K Ca GOT T-Bili CK Alb HAST Crea Phos PTH OC
Genotype mM mM mM U/l µM U/l g/l mM µM mM pg/ml ng/ml
Hyp
n = 3 3 3 3 3 3 3 3 3 3 3 4
mean 143.17 2.16 1.05 22.33 1.56 37.67 16.36 3.27 5.33 0.86 70.17 15.25
SD 1.40 0.13 0.13 4.51 0.35 27.54 1.21 0.41 0.58 0.18 48.66 6.55
rescue
n = 7 7 7 7 7 7 7 7 7 7 7 10
mean 143.34 2.35 1.05 17.71 1.33 47.29 16.05 4.47 7.00 0.98 34.80 14.89
SD 3.78 0.53 0.02 8.24 0.59 65.18 1.30 0.91 1.00 0.13 25.19 9.43
wild-type
n = 8 8 8 8 8 8 8 8 8 8 8 8
mean 144.93 2.02 1.05 13.00 1.53 20.00 15.35 3.86 6.88 1.42 16.33 11.33
SD 3.39 0.15 0.03 2.73 0.30 6.93 0.63 0.48 1.13 0.13 13.31 2.56
Table 8
Serum values for rescue mice
 
 
 
Abbreviations 
 
BW  –  Body Weight 
Ca    – Calcium 
Na    – Sodium 
K      – Potassium 
SD    – Standard deviation 
GOT –   Glutamate  
Oxaloacetate  
Transaminase 
AP    – Alkaline 
Phosphatase 
T-bili – T billirubin 
CK    – Creatine kinase 
Alb    – Albumin 
HAST – N-hydroxyarylamine          .  
                      sulfotransferases  
Crea  – Creatinine 
Phos – Phosphorous 
PTH –    Parathyroid                        
               hormone  
OC   –  Osteocalcin 
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Rescue mice 
 
 
Na / Crea K / Crea Ca / Crea Crea P / Crea
Genotype mM/mM mM/mM mM/mM mM mM/mM
Hyp
n = 3 3 3 3 3
mean 53.55 69.83 1.44 1.97 22.89
SD 5.86 6.90 0.36 0.83 9.72
rescue
n = 5 5 5 5 5
mean 48.00 54.91 0.78 3.06 27.07
SD 7.99 18.44 0.33 0.76 8.44
wild-type
n = 8 8 8 8 8
mean 63.08 68.76 1.36 1.96 11.95
SD 24.04 10.15 0.73 0.66 4.26
Table 9
 Urine vales for rescue mice
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4.5 Assay of bone mineral density 
 
An analysis of the bone mineral density revealed insignificant effects of hPHEX 
transgene in both the 236 and 237 lineages.  Measurements of the femoral shaft and 
femoral metaphysis showed the mineralized bone densities, areas and cortical 
thickness remained constant (Tables 10 - 11 and figures 26 - 29). 
 
4.5.1 Female β-actin-hPHEX 236 
Table 10
total total cortical cortical cortical
density area density area thickness
mean 699.37 1.772 1193.98 0.910 0.228
wild type SD 26.58 0.069 17.32 0.042 0.010
mean 700.30 1.784 1199.31 0.914 0.227
transgenic SD 27.90 0.067 21.11 0.032 0.008
total cortical subcort. trabecular total trabecular Cortical subcort.
density density density area area area
mean 558.08 792.82 224.97 3.706 1.391 2.314
wild type SD 23.40 23.91 25.66 0.103 0.171 0.141
mean 556.51 803.34 215.84 3.637 1.407 2.228
transgenic SD 23.35 26.92 25.65 0.126 0.214 0.223
Femoral shaft 
Femoral Metaphysis
 
Figure 26 
Shaft cortical density and metaphysis cortical sub-
cortical density comparisons. 
Figure 27 
Metaphysis trabecular density. 
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4.5.2 β-actin-hPHEX 237 
 
Table 11
total total cortical cortical cortical
density area density area thickness
Female mean 678.20 1.813 1171.80 0.920 0.226
wild type SD 34.14 0.076 41.57 0.035 0.007
Female mean 639.51 1.687 1120.10 0.821 0.207
transgenic SD 59.47 0.151 72.42 0.099 0.020
Male mean 605.67 1.881 1112.93 0.870 0.207
wild type SD 39.24 0.058 41.14 0.059 0.014
Male mean 584.85 1.912 1104.85 0.848 0.198
transgenic SD 17.35 0.099 28.47 0.053 0.009
total cortical subcort. trabecular total trabecular Cortical subcort.
density density density area area area
Female mean 563.46 832.26 214.18 3.620 1.504 2.119
wild type SD 29.10 23.45 9.79 0.166 0.123 0.161
Female mean 508.11 750.04 219.56 3.473 1.535 1.939
transgenic SD 44.02 82.20 36.94 0.218 0.124 0.202
Male mean 470.26 680.86 263.18 3.982 1.883 2.101
wild type SD 17.48 42.86 24.77 0.165 0.153 0.198
Male mean 436.36 695.27 226.16 3.879 2.068 1.812
transgenic SD 20.66 32.84 24.86 0.192 0.125 0.194
Femoral shaft 
Femoral Metaphysis
 
 
 
 
 
Figure 28 
Femoral shaft cortical density for both 
genders 
Figure 29 
Femoral metaphysis trabecular density 
for both genders 
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4.5.3 Bone density is increased in rescue mice 
 
Once again the analysis of the bone mineral density of the rescue mice showed 
significant normalization from the Hyp mutant toward wild-type mice.  Femoral shaft 
measurements for total density increased in rescue mice while total area was 
insignificantly changed (figures 30 - 31 ).  Values for cortical density, area and 
thickness all displayed significant changes toward normalization (table 12 and figures 
32 - 33).  
 
table 12
total total cortical cortical cortical
density area density area thickness
Hyp mean 369.10 2.060 835.30 0.620 0.130
SD 24.51 0.070 28.63 0.040 0.010
Rescue mean 529.15 2.310 1027.46 0.980 0.210
SD 59.79 0.310 76.01 0.210 0.030
Wild- mean 598.13 1.99 1116.94 0.91 0.21
type SD 20.79 0.09 24.8 0.04 0.01
Femoral shaft 
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Figure 30 
Femoral shaft total area  
Figure 31 
Femoral shaft total density  
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Rescue Mice Femoral Metaphysis 
 
In an examination of the metaphysis, significant changes were noted in the total 
density, cortical-subcortical density and trabecular density (table 13 and figures 34 - 
36) 
 
 
Table 13
total cortical subcort. trabecular total trabecular Cortical subcort.
density density density area area area
Hyp mean 288.68 584.41 110.69 3.752 2.323 1.430
mice SD 4.76 26.58 20.30 0.633 0.385 0.283
Rescue mean 383.06 644.15 180.01 4.616 2.530 2.085
mice SD 51.52 27.23 42.45 0.656 0.199 0.501
Wild- mean 424.09 696.72 221.20 3.645 2.060 1.584
type SD 15.40 17.12 13.46 0.093 0.099 0.117
Femoral Metaphysis
 
 
 
Femoral shaft cortical density
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Figure 32 
Femoral shaft cortical thickness 
Figure 33 
Femoral shaft cortical density 
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4.6  Histological examination of femurs 
 
The femoral epiphysis of the 236, 237 was stained for mineralized bone (black in 
figures 37,40) with the Van Kossa/McNeal technique.  Gross examination of the 
sections reveals no difference between wild-type and transgenic samples.  TRAP 
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Figure 35 
Comparison of rescue mice with Hyp 
and wild-type mice metaphysis 
trabecular density 
Figure 36 
Comparison of rescue mice with Hyp 
and wild-type mice metaphysis total 
density 
Figure 34 
Comparison of rescue mice with Hyp 
and wild-type mice metaphysis cortical 
sub-cortical density 
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staining of sections from 236 β-actin hPHEX mice  and wild-type littermates indicate 
no difference in osteoclast proliferation (figure 38, arrows).  Calcein staining of 
sections with a time delay of three days between injections allowed the rate of bone 
remodeling to be visualized.  Sections from the 236 and 237 transgenic animals 
appear identical to wild-type sections, indicating a similar remodeling capacity 
(figures 39, 41 - 42). 
 
Staining of rescue mice sections for mineralized bone in the growth plate and the 
secondary spongiosa clearly reveals better, though still somewhat abnormal, 
organization of chondrocytes and the growth plate compared to Hyp sections (figure 
43 -44).  Fluorochrome staining (figure 45) displays an improvement of bone 
remodeling in rescue mice over Hyp mice, but clearly not as defined as seen in the 
wild-type femur.
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 β-actin-hPHEX 236  
 
 
Figure 37:    12 week old mouse femur epiphysis stained for mineralized bone using 
von Kossa/Mac Neal protocol.  
2.5X.  A)wild-type  B)transgenic 
 
 
Figure 38:    12 week old mouse femur stained using TRAP protocol (osteoclasts 
indicated by arrows).   20X.  A)wild-type  B)transgenic 
 
 
Figure 39:    Fluorochrome (calcein) labeling in femor of 12 week old mouse, viewed 
under blue excitation.  40X.  A) wild-type  B) transgenic
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 β-actin-hPHEX 237 
 
Figure 40:  12 week old mouse femur epiphysis stained for mineralized bone using 
von Kossa/Mac Neal protocol.  
2.5X.  A)male wild-type  B) male transgenic  C) female transgenic  
 
 
Figure 41:  Fluorochrome (calcein) labeling in femor of 12 week old mouse, viewed 
under blue excitation. 
40X.  A) male wild-type  B) male transgenic  
 
 
Figure 42:  Fluorochrome (calcein) labeling in femor of 12 week old mouse, viewed 
under blue excitation.  
40X.  A) female wild-type  B) female transgenic  
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 Rescue mice 
 
 
Figure  43:  12 week old mouse femur epiphysis stained for mineralized bone using 
von Kossa/Mac Neal protocol.  
2.5X.  A)wild-type  B) Hyp  C) rescue  
 
 
 
Figure  44:  12 week old mouse femur secondary spongiosa stained for mineralized 
bone using von Kossa/Mac Neal protocol.  
20X.  A)wild-type  B) Hyp  C) rescue 
 
 
 
Figure 45:  Fluorochrome (calcein) labeling in femor of 12 week old mouse, viewed 
under blue excitation. 
40X.  A)wild-type  B) Hyp  C) rescue 
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5 Discussion 
The pathways leading to phosphate homeostasis are affected by many factors and 
involve varied and complicated feedback loops all of which insure a stable 
concentration of phosphate available throughout the microcellular landscape.  The aim 
of this doctoral work has been to characterize mice overexpressing the phosphate 
regulating gene with homologies to endopeptidases on the X chromosome (PHEX).  
We also analyzed the outcome of a cross between the newly created human PHEX 
(hPHEX) transgenic mice and Hyp mice carrying a spontaneously mutated copy of 
the mouse PHEX (mPHEX)gene. 
 
PHEX has 95% DNA similarity between human and mouse genomes and shares the 
same exon organization.  PHEX is a gene crucial to renal phosphate reabsorption and 
phosphate homeostasis in general, as well as playing a role in the mineralization of 
bone.  It has been identified as the causative factor in the human disorder X-linked 
hypophosphatemia (XLH), a disordered primarily defined by its low serum phosphate 
levels.  Patients with XLH suffer from hypophosphatemia as well as other 
phenotypical abnormalities (rickets, shortened stature, etc.) due to deletions or 
nonsense mutations in the carboxy terminal end of the PHEX gene.  These mutations 
lead to the ablation of the extracellular catalytic domain.   A spontaneous mutation in 
mouse has been characterized and shares the same physiological traits as human XLH 
patients.  The abnormalities inherent in this mutant mouse, labeled Hyp for 
hypophosphatemia, have also been attributed to the (mPHEX) carboxy terminus being 
truncated between exon 15 and 16.  Hypophosphatemia studies involving parabiosis 
between Hyp and wild-type (WT) mice compared to WT with WT pairings indicated 
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a circulating factor is involved in the phosphate regulating pathway (Meyer et al, 
1989).  This factor was named phosphatonin.  Further hypophosphatemia studies 
involving renal transplant between Hyp and WT mice proved there was no intrinsic 
defect in the kidneys of Hyp mice (Nesbitt et al.,1992).  It has been shown that mRNA 
and protein levels of the Na+ dependent phosphate transporter type II (Npt2), which is 
expressed in the proximal tubule of the kidney, are compromised by 50% in Hyp mice 
(Tenenhouse et al, 1994).  This reduction is ultimately responsible for 
hyperphosphaturia (Levi, 2000).   
 
Secondary to hypophosphatemia, osteoblasts in Hyp mice exhibit an intrinsic 
mineralization defect.  Ecarot-Charrier et al. (1988) were able to show that the ability 
of the Hyp osteoblasts to mineralize osteoid (unmineralized bone matrix) is seriously 
compromised in vivo.  Hyp periosteal cells produced a matrix with an increased 
osteoid thickness when transplanted in normal gluteal muscle compared to wild-type 
periosteal cells transplanted into the same environment.  In addition, the secondary 
mouse PHEX (mPHEX) defect allows for the accumulation of an unknown factor that 
inhibits osteoid mineralization in vitro.  These studies indicate the production of a 
mineralization inhibitory factor by Hyp osteoblasts (Xiao et al., 1998). 
 
PHEX expression has been identified predominantly in osteoblasts, and odontoblasts 
(Ruchon et al., 1998). Expression levels are seven fold higher in bone than found in 
lung, muscle or ovary, with no expression detected in the kidney.  The specific 
substrate(s) for PHEX endopeptidases activity have thus far not been fully identified 
and/or characterized.  PHEX endopeptidase activity has been verified by its ability to 
cleave several non-specific substrates to include PTH (1-34), PTH (1-38), FGF-23, 
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ZAAL-pNA and [Leu]enkephalin, of which the latter two are specific substrates of 
related endopeptidases.  It remains to be conclusively determined, but FGF-23 could 
be a PHEX specific substrate.  FGF-23 has been recently identified as the causative 
factor in the disease autosomal dominant hereditary rickets (ADHR).  FGF-23 is a 
32kDA circulating protein whose expression has only been identified in tumors 
causing tumor induce osteomalacia (TIO) and the forebrain (Shimada et al., 2001).   
In ADHR patients, FGF-23 contains a mutation (∆FGF-23) in its cleavage site which 
negates endopeptidase activity.  Cleavage studies indicate PHEX is unable to cleave 
∆FGF-23.  If PHEX tertiary folding is similar to that of the related and already 
crystallized NEP structure, then with its small size, FGF-23 would likely fit into the 
catalytic pocket formed by PHEX (Oefner, 2000)  In further studies FGF-23 was 
cleaved by PHEX and demonstrated to inhibit renal phosphate cotransport (Bowe et 
al., 2001) 
 
From the evidence presented so far, the following models for regulation of phosphate 
resorption were established. 
 
Figure 46:  Normal phosphate resorption 
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Normal : Phosphate is resorped principally through the actions of Npt2 in the 
proximal tubules of the kidney.  Npt2 is negatively regulated through a pathway 
dependent on the circulating levels of active FGF-23.  The levels of active FGF-23 are 
regulated by the inactivating endopeptidase activity of PHEX (figure 46). 
 
Figure 47:  XLH / Hyp disorder 
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XLH / Hyp : In Hyp mice and XLH patients, the catalytic domain of PHEX is 
destroyed, and the resultant buildup of active FGF-23 causes a drastic reduction in 
Npt2 levels which results in the development of hypophosphatemia (figure 47). 
 
Figure 48:  TIO / OHO disorder 
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TIO / OHO : The supraphysiological levels of active FGF-23 caused by tumors 
overwhelm the endopeptidase activity of PHEX, which depletes Npt2 levels and 
allows hypophosphatemia to develop.  The complete removal of the tumors returns 
the active FGF-23 levels to normal and hypophosphatemia is alleviated (figure 48). 
 
Figure 49:   ADHR disorder 
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ADHR : FGF-23 in mutated in such a way as to obstruct cleavage by the 
endopeptidase while retaining its activity in the regulatory pathway of Npt2.  Npt2 
expression levels are again reduced and hypophosphatemia results (figure 49).   
 
In an examination of the PHEX translation start site, it is unusual to find a pyrmidine 
instead of a purine residue at position -3.  In higher vertebrates 97% of translation 
start sites conform to the classic Kozak sequence (Kozak, 1991).  The other three 
percent, to include PHEX, are believed to be strongly regulated genes that involve 
tight post-transcriptional control (figure 50).   
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Figure 50  Translational start site of human and mouse PHEX. 
 
 
human  CTCTCTACGGCCCTTCTGATGGAAGCAGAAACAGGGAGCAGCGTGGAGACT 
mouse  TTCTCTCCAGCCCTTCTGATGGAAGCAGAAACAGGGAGCACCATGGAGACT 
 
human     M  E  A  E  T  G  S  S  V  E  T   
mouse     M  E  A  E  T  G  S  T  M  E  T   
 
 
 
A post-tranlational modification consensus sequence, CXXX box motif,  is located at 
position 746 – 749 (CRLW)  of the carboxy terminus in both human and mouse 
sequences.  This consensus sequence has been identified as a possible site of 
prenylation, which is involved in a number of different processes to include regulation 
of protein function and protein-protein interactions.  (Lipmann et al., 1998).   
 
To date there have been few transgenic or knockout mouse models that are 
characterized by a biochemical change in the phosphate homeostasis.  Since the lack 
of PHEX leads to such a significant drop in serum phosphate levels of XLH patients 
and in the Hyp mouse, it would be reasonable to expect that an increase in the 
expression of PHEX could also alter the serum phosphate levels. 
 
Many endopeptidases point of effect is within the tissues of greatest expression.  
Therefore, the osteoblast specific promoter for the osteocalcin gene (OG2) was used 
in the creation of the first transgenic construct.  Osteocalcin is the only gene thus far 
identified as being expressed exclusively in mature osteoblasts and odontoblasts.  The 
1.3kb of mOG2 5’flanking region contains two osteoblast nuclear protein binding 
sites that act as cis-acting transcriptional elements for increased expression (Ducy and 
Karsenty, 1995).  The osteoblast specific transgene was successfully shown to 
produce a protein in vitro and the pronuclear injection of this transgene created three 
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different transgenic lines of mice carrying the hPHEX gene.  These transgenic 
lineages displayed between one and four integration sites of hPHEX.  Expression 
studies in all three transgenic lineages showed negative results for the transcription of 
mRNA species or the subsequent translation of the hPHEX protein.  The transgenic 
construct may be inhibited from being expressed due to its site of integration, or some 
form of genomic transcriptional control elements around the sites of integration. 
 
Liu et al. (2002) were able to produce multiple PHEX transgenic lineages using the 
same principle transgene construction strategy.  Male PHEX were bred with 
heterozygous female Hyp mice and the offspring analyzed.  The Hyp/PHEX offspring 
obtained from the matings displayed persistent hypophosphatemia but a significant 
improvement in the osteoblast mineralization defect was detected (Liu et al., 2002), 
similar to what we found in our β-actin-hPHEX 236 /Hyp offspring. 
 
β-actin is a ubiquitously expressed gene with relatively high expression levels in all 
non-muscle cell types.  The β-actin promoter has been used successfully to create 
transgenic mice with ubiquitous expression patterns of multiple genes.  The β-actin 5’ 
flanking region as well as 5’ untranslated region and intervening sequence I (IVSI) 
was used to provide the promoter activity for the transgene.  The inclusion of these 
sequences allows for gene expression in muscle cells as well as non-muscle cell types.  
The exclusion of muscle cells types for the expression of β-actin is conferred by 
sequence 3’ of the IVSI region and was not included in the transgene construct 
(Gunning et al., 1987).   A transgene was constructed using four kilobases of 5’ β-
actin flanking region as a promoter for hPHEX and a SV-40 poly-A tail.  After 
5. Discussion 
 
 
 91
confirming transcription and translation of the transgene in vitro, two lines of 
transgenic mice were created, designated β-actin 236 and β-actin 237.  The expression 
of the hPHEX mRNA species was confirmed by RT-PCR in multiple tissues for both 
lineages.  Although the expression of the transgene could be seen by RT-PCR, 
Northern blot analysis for both lineages was negative.  RT-PCR can detect much 
lower transcript copy number than Northern blot.  Development of Northern blots of 
total RNA at four weeks exposure to BioMax film showed no hybridization at all 
(results were confirmed by multiple investigators).  This was unexpected, as the β-
actin gene is highly expressed as were other transgenes using this promoter.  If PHEX 
is indeed a strongly regulated gene, then some form of pre- or post-transcriptional 
control could be responsible for the low hPHEX transcript numbers being detected.  
The makeup of the transgene or PHEX cDNA itself may have attracted inhibitory 
control elements or there may have been a degradation of the majority of transcripts 
shortly after completion of transcriptional events.   
 
Due to the relatively low expression levels of hPHEX, it was not surprising to find 
that the biochemical phenotype of the transgenic mice was almost unchanged from 
that of the wild-type controls.   If hPHEX is indeed an inactivating endopeptidase as 
we hypothesize, an increase in serum phosphate levels would have been expected.   
The largest increase in serum phosphate levels (0.12 mM) seen in β-actin-hPHEX 237 
female mice was not statistically significant.  Increased expression of PHEX in 
osteoblasts of the β-actin-hPHEX 236 and β-actin-hPHEX 237 transgenic lineages did 
not affect the bone mineralization as measured in bone mineral density studies 
(pQCT).  Histological sections of the distal femur also did not show differences 
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between transgenic animals and corresponding controls.  One or more of the other 
factors in the phosphate regulatory pathway may compensate for the slightly increased 
endopeptidase activity of hPHEX in our transgenic lineages.  It is also possible that 
the levels of overexpression found in the β-actin-hPHEX 236 and β-actin-hPHEX 237 
lineages were not sufficient to produce a physiological response.  The transcription 
factor Sox-9 is crucial to chondrogenesis and has been shown to influence PHEX 
promoter activity with up to 6 fold increases of PHEX expression in co-culture 
experiments.  Also identified in the 2736 base pair promoter region of the mPHEX 
gene were 32 consensus cis-acting elements that are conserved between mouse and 
human (Liu et al., 2001).  By replacing the hPHEX promoter with the OG2 and β-
actin promoters we may have disrupted potential binding by these elements that could 
be essential for the correct transcription or function of the hPHEX protein in vivo. 
 
To further investigate if there is a possible effect in the re-expression of hPHEX in the 
Hyp mouse where serum phosphate levels are reduced, the β-actin-hPHEX 236 
transgenic lineage was crossed with Hyp mice and the offspring (rescue mice) 
characterized.  Rescue mice were the result of a male hPHEX transgenic animal 
mated with a homozygous Hyp female.  
 
From gross examination it was obvious that the rescue mice had improved body 
weight and long bone formation.  However, in the analysis of the biochemical data, 
there was no significant change in the different values that were examined.  Phosphate 
was increased from the low levels found in Hyp mice, but not at a significant level.  
Body weight from the Hyp mice was 65% of the wild-type mice whereas the rescue 
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mice body weight was 89% of the wild-type controls.  The increase in body weight 
was associated with an increase in bone mineral density as measured by pQCT..  The 
rescue mice femurs displayed a marked increase in the longitudinal growth and 
mineralization of femurs.  pQCT data indicated that bone mineral density in both the 
femoral shaft and the metaphysis was significantly improved relative to Hyp mice.  
Von Kossa/MacNeal stained histological sections of rescue mice compared to Hyp 
and wild-type sections clearly show the reorganization of the rescue growth plate 
(figure 43 - 44).  Fluorochrome labeling of rescue mice sections displayed more 
organized bone formation, but compared to the wild-type sections still abnormal.  Hyp 
sections contrarily reveal a very disorganized or jumbled calcein marking (figure 45).  
These results indicate that although the deletion mutation of PHEX in the Hyp mouse 
accounts for two major phenotypical changes, they are partially separate events.   
Hypophosphatemia caused by the lack of functional PHEX is not solely responsible 
for the mineralization defects in the osteoblasts.  The overexpression of hPHEX 
within the microenvironment of the osteoblasts in our transgenic mice has an effect on 
a substrate or pathway that to date has not been identified.  However, it can not be 
discounted that the ubiquitous expression of hPHEX in the β-actin-hPHEX 236 
lineage has influenced the mineralization of the osteoid from somewhere other than 
the osteoblast microenvironment. 
5. Discussion 
 
 
 94
5.1 Conclusion 
Our creation of osteoblast specific hPHEX transgenic mice has been unsuccessful 
using the current transgene construct therefore a different strategy must be developed.  
The future strategy may be to use multimers of the cis-acting transcriptional elements 
identified in the mOG2 5’ flanking region.  Using multimers of these two regions has 
produced greater than 200 fold increased expression in vitro compared to single copy 
constructs (Ducy et al., 1995).   
β-actin-hPHEX 236 and β-actin-hPHEX 237 transgenic lineages expressed the 
hPHEX gene across multiple tissues as is consistent with the β-actin promoter region 
used.  The transgenic overexpression of hPHEX produced surprisingly low levels of 
hPHEX.  This minor overexpression was unable to influence serum phosphate levels 
or significantly change any of the other biochemical parameters involved in phosphate 
homeostasis.  However, the transgene was able to partially rescue the intrinsic defect 
identified in Hyp osteoblasts, and mirrored in XLH patients, as seen in rescue mice 
created through a crossing of the 236 β-actin hPHEX lineage with Hyp mice.  The 
growth plate of femurs from rescued mice displayed better chondrocyte organization 
than Hyp controls.  Despite persistent hypophosphatemia there was greater 
mineralization measured in both distal femur and femur shaft of rescue mice.  The 
increased mineralization of the osteoid in the rescue mice over the Hyp mice was 
measured as, metaphysis total density 70%, metaphysis trabecular density 62.7% and 
femoral shaft cortical density 68.2% with all p values less than 0.05.  It would appear 
that PHEX not only affects the pathway or regulatory elements for NPT2 expression 
and therefore phosphate resorption in the kidney, but in a separate regulatory pathway 
affects the mineralization of osteoid. 
5. Discussion 
 
 
 95
Future direction should be to study the osteoblast function of the rescue mice in vitro 
and in vivo.  Further attempts for the creation of a highly overexpressing hPHEX 
mouse through the use of other promoters or under the influence of Sox-9 may reveal 
more significant variations in the biochemical data and/or abnormalities in bone 
growth and density.
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